Trading Analysis Report: MKSI¶

Analysis date: 2026-10-21
Rating: Underweight
Generated: 2026-10-21 12:17:37
TradingAgents 0.6.0: anthropic, deep claude-opus-5-5, quick claude-sonnet-5-5
Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

I. Analyst Team Reports¶

Market Analyst¶

Current Price: 215.51 Price As Of: 2026-10-21

MKSI (MKS Inc., NMS) Technical Report, as of 2026-10-21¶

1. Summary¶

MKSI is in a clear, strong downtrend on all three supertrend timeframes. It is also short-term oversold, with a completed daily TD-9 buy setup, RSI near 30 and a price just above the lower Bollinger Band. The higher-timeframe evidence (weekly and monthly) is still bearish, and the exhaustion evidence is mostly on the daily chart, which carries the least weight. The picture is a possible relief bounce inside a downtrend, not a confirmed reversal.

The verified snapshot and the OHLCV pull agree on the latest bar, so I found no data conflicts. The latest bar has volume of 717,467, well below the recent daily range of roughly 1.0–2.6M. If the session was not complete when the data was pulled, today's close may change.

2. Price Structure (12-month data)¶

Run-up: The closing low in the pulled window was 133.86 on 2025-10-22. The stock more than tripled to a closing high of 444.39 on 2026-06-30, with an intraday high of 447.20 that day.
Reversal: From that peak the stock has lost about 51.5% on a close-to-close basis (444.39 to 215.51).
Lower highs and lower lows since the peak:
Rallies topped at 329.03 on 2026-08-04, 270.29 on 2026-09-11 and 286.38 on 2026-10-06.
Intraday lows stepped down from 255.92 on 2026-07-29 to 228.46 on 2026-09-15, then 212.35 on 2026-10-15 and 205.62 on 2026-10-20.
Gap-downs and recent selling:
The closes of 315.41 on 07-27, 285.04 on 07-28 and 257.37 on 07-29 came with volumes of about 1.4M, 2.0M and 2.5M. I have no news or earnings data here, so I can't name the cause.
On 2026-09-14 the stock fell from 267.31 to 239.27 (about -10.5%).
The latest leg ran from 281.41 on 2026-10-06 to 211.14 on 2026-10-20 (about -25%). Volume was elevated on 10/15 (2.57M) and 10/16 (1.60M).
Current base attempt: The four closes from 10/16 to 10/21 all sit between 211.14 and 215.51 (214.83, 215.41, 211.14, 215.51). The 10/20 close of 211.14 was the lowest close since 2026-03-30 (210.12). Today's bar opened at 216.35, traded 213.19–218.13 and closed up about 2.1% on the day. Selling has paused, but one up day is not a reversal.

3. Trend Indicators¶

Moving averages (verified snapshot) - 10 EMA: 230.94 - 50 SMA: 261.29 - 200 SMA: 277.08

Price is below all three. The 50 SMA is below the 200 SMA, which is a bearish long-term alignment. The 10 EMA is about 7% above price and falling, so it acts as the nearest dynamic resistance. A close back above it would be the first sign of short-term improvement.

SuperTrend (14, 3x ATR) - Weekly (Tier 1, primary): DOWN. The trailing stop is 319.34 and the close is 32.51% below it. - Monthly (Tier 2): DOWN. The stop is 413.58 and the close is 47.89% below it. - Daily (Tier 3): DOWN. The stop is 249.15 and the close is 13.50% below it.

All three timeframes agree, so there is no conflict to resolve. A daily flip would need a close above 249.15 (the stop level can move over time). A weekly flip is a long way off, which is why a bounce would not by itself change the primary trend.

ADX - ADX is 45.07, up from 7.11 on 2026-10-07. The sequence was 22.99 on 10/14, 30.05 on 10/15, 35.10 on 10/16, 38.70 on 10/19, 42.80 on 10/20 and 45.07 on 10/21. - The market has moved from directionless (ADX under 10 in early October) to a strongly trending state in about two weeks. Because price fell throughout, that trend is down. - I did not pull +DI and -DI, so the direction is inferred from price and supertrend, not from DI values. - ADX at this level means trend-following shorts or avoidance have worked in this window. A mean-reversion long has to fight a strong trend. A high ADX can also precede exhaustion, but ADX alone doesn't signal that.

4. Momentum¶

RSI - RSI is 30.60. It was 59.12 on 10/06 and fell to a window low of 27.12 on 10/20. - Today's reading is a small uptick off oversold territory. - In a strong trend (ADX above 40), RSI can stay near or below 30. A failed rally that stalls in the 40s would confirm bears are still in control.

MACD (verified snapshot) - MACD is -13.49 and the signal line is -8.34. The histogram is -5.15. - The histogram turned negative on 10/13 (-0.75). It reached its most negative reading on 10/20 (-5.61), and today is slightly less negative at -5.15. - That is a very early sign of the bearish momentum slowing, but it is one data point. Both lines are well below zero, which is a bearish regime.

5. Volatility and Bands¶

ATR: 12.24, about 5.7% of price, which is high. It is down from 13.07 on 10/16 and from 13.67 on 09/21. For sizing, a 1x ATR move is about 12 points. A 2x ATR stop is about 24 points.
Bollinger Bands (verified snapshot): The upper band is 299.03, the middle is 251.81 and the lower is 204.60. The bands are wide, about 37% of the mid-line. Price sits at roughly the bottom 12% of the band range, close to the lower band. The 10/20 intraday low of 205.62 came very near the 204.60 lower band.
In a strong downtrend, price can ride the lower band, so touching it is not a buy signal by itself. The middle band at 251.81 is a plausible rally ceiling in a relief scenario.

6. Exhaustion and Stretch¶

TD Sequential (TD-9) - Daily: +9, a completed buy setup. This is a reversal watch. - Weekly: +3 of 9. Monthly: +3 of 9. - The higher timeframes carry more weight, and both are early in their counts. The daily 9 supports a bounce but does not override the weekly and monthly setups still in progress. If the weekly count kept building by one each week, a weekly 9 would still be several weeks away. That depends on the weekly closes continuing lower.

Z-score (20-period) - Daily: -1.54. Weekly: -1.53. Monthly: +0.20. - The daily and weekly readings are below the mean but not at the -2 threshold that flags a statistical extreme. So price is stretched, but not at an extreme, and there is room for more downside before |z| reaches 2. - The monthly reading near zero shows that the monthly 20-bar mean is still well above price after the large run-up.

7. Volume¶

OBV - OBV peaked in the window at 42.42M on 10/06. It fell to a low of 31.87M on 10/16 and is now 32.78M. - OBV has fallen with price, so it confirms the decline rather than diverging from it. - On 10/20 the close was lower (211.14 versus 214.83 on 10/16), while OBV (32.06M) was slightly above its 10/16 level. That is a possible mild bullish divergence, but it is tiny and not meaningful on its own. - The elevated volume on the 10/15 and 10/16 down days is consistent with active distribution or capitulation-type selling. I can't tell which from the data alone.

8. Reference Levels (all taken from the data above)¶

Overhead levels:
218.13: today's high.
228.52: the 10/15 close.
230.94: the 10-day EMA.
234.50: the 10/14 close.
249.15: the daily SuperTrend stop.
251.81: the Bollinger middle.
261.29: the 50 SMA.
277.08: the 200 SMA.
319.34: the weekly SuperTrend stop.
Downside levels:
213.19: today's low.
211.14: the 10/20 close.
205.62: the 10/20 intraday low.
204.60: the lower Bollinger Band.
208.12: the 3/30 intraday low.
200.16: the 3/9 intraday low.
Prior rebounds: After the 3/30 close of 210.12, the next close was 229.42 on 3/31. After the 3/9 low of 200.16, the close was 217.99. These are single instances and not proof that the zone will hold now.

9. Scenarios Supported by the Tools¶

Bounce scenario: Daily TD-9 complete, RSI near 30, price near the lower band, a four-day base at 211–216 and a slightly improving MACD histogram. Confirmation would be a close above the 10 EMA (~230.94) with rising volume. Beyond that, the 228–235 area and the 249.15 daily SuperTrend stop would be the next tests.
Continuation scenario: All SuperTrend tiers are down, ADX is at 45, price is under the 10, 50 and 200 averages, and the weekly and monthly TD counts are early. A close below 205.62 or the 204.60 lower band would bring the 200.16 area into play, and z-score could approach -2.
Risk sizing: ATR is about 12, so stops inside 1x ATR (about 12 points) are likely to be hit by normal daily noise.

10. Limits of This Analysis¶

I have no fundamental, news or earnings data, and I can't attribute the July, September or October drops to any event.
I did not pull +DI/-DI, MFI, or the stochastic family.
Today's bar may be incomplete, given its low volume.

Key Points Table¶

Category	Indicator	Reading (2026-10-21)	Interpretation
Price	Close / Range	215.51; high 218.13, low 213.19, volume 717,467	Up about 2.1% on the day; volume is low, so the bar may be incomplete
Structure	Peak to now	444.39 (2026-06-30) to 215.51	About -51.5%; lower highs and lower lows
Trend	SuperTrend weekly (primary)	DOWN, stop 319.34, close 32.51% below	Bearish primary trend
Trend	SuperTrend monthly	DOWN, stop 413.58, close 47.89% below	Bearish regime
Trend	SuperTrend daily	DOWN, stop 249.15, close 13.50% below	A close above 249.15 would flip the daily trend
Trend	10 EMA / 50 SMA / 200 SMA	230.94 / 261.29 / 277.08	Price below all; 50 below 200
Trend strength	ADX	45.07 (from 7.11 on 10/07)	Strong trend, down given price action; DI not pulled
Momentum	RSI	30.60 (low 27.12 on 10/20)	At the oversold threshold; can stay low in a strong trend
Momentum	MACD / signal / histogram	-13.49 / -8.34 / -5.15	Bearish, but the histogram is narrowing from -5.61
Volatility	ATR	12.24 (about 5.7% of price)	High volatility; stops need room
Volatility	Bollinger (lower / mid / upper)	204.60 / 251.81 / 299.03	Price near the lower band; the middle band is a rally ceiling
Exhaustion	TD-9 daily / weekly / monthly	+9 / +3 / +3	Daily reversal watch; weekly and monthly are early
Stretch	Z-score daily / weekly / monthly	-1.54 / -1.53 / +0.20	Below the mean but not at the -2 extreme
Volume	OBV	32.78M (peak 42.42M on 10/06; low 31.87M on 10/16)	Confirms the decline; a tiny possible divergence on 10/20
Overall	Bias	Bearish primary trend, oversold bounce setup	The daily exhaustion signals conflict with the weekly and monthly trend

Sentiment Analyst¶

Overall Sentiment: Mildly Bullish (Score: 6.0/10) Confidence: Low

1) SOURCE-BY-SOURCE BREAKDOWN

News (Yahoo Finance, 11 headlines, 2026-10-14 to 2026-10-21; headlines only, no article bodies): The dominant event is MKS Inc. agreeing to sell its Ophir Optics unit to TTM Technologies for about $650M in all cash. It was announced pre-market on 2026-10-19 and carried by GlobeNewswire (both the MKS and TTM releases), MT Newswires and Investing.com. Both the Investing.com and MT Newswires headlines say MKSI shares rose (MT Newswires says pre-bell). The size of the move is not provided. Secondary items are Zacks quant-style pieces: 'Wall Street Analysts Think MKS (MKSI) Could Surge 60.28%' (implied upside to consensus price targets, which can be stale or widely dispersed, so treat with caution), 'MKS (MKSI) Forms Hammer Chart Pattern' (a reversal-candidate technical framing that implies the stock had been falling), 'MKSI vs. ROK' (value comparison), and 'AEIS ... Can It Beat KLAC and MKSI?' (peer comparison). The Trefis pieces on KLA and Coherent and the TTMI 'trading up' article are peripheral peer or counterparty context. Net news tone is mildly positive, event-driven and fact-based, with no MKSI-specific negative headline in the window.

StockTwits (11 most-recent messages, 2026-10-14 to 2026-10-20): Bullish 2 (18%), Bearish 0 (0%), Unlabeled 9. Zero bearish tags is notable, but with only two labeled posts the ratio is not statistically meaningful. One of the two bullish tags (@KlausSchwab) is about buying $TTMI, the acquirer, not MKSI. MKSI-specific labeled bullishness is therefore effectively one post (@BatteryBoy, written before the announcement: 'have been waiting patiently for entry'). The unlabeled posts lean constructive on the deal and valuation: - @shimblum calls $650M for a small piece of the company 'brilliant' and says 'cash is king'. - @MostHated says 'buying here' (10-16). - @Tickrtrends says MKSI moved from fairly valued to undervalued (market cap ~$14.5B, trailing P/E ~21x). - @filecrux says the price is over 18x the unit's projected FY2026 adjusted EBITDA (under ~$36M of EBITDA) and about 4.5% of a ~$14.53B market value at the $214.83 close on 10-16.

Context and caution: on 10-16 @shimblum asked 'where is the bottom?' while noting ~14x next year's earnings, which points to a recent drawdown and a dip-buyer versus falling-knife debate before the deal. @eWhispers noted semis (SOXX) had the largest relative-strength drop of the prior two weeks, basically since $MU missed earnings expectations. @Techdamentals offered a structural bull thread: vacuum and flow-control subsystems sit under any process change for a new vertical surrounded-gate DRAM structure, though it framed this as a long process-development program, not a near-term driver. @notreload_ai and @Rayvio_News_Filter are news relays with no opinion.

Reddit: skipped (disabled by sentiment_include_reddit config). No r/wallstreetbets, r/stocks or r/investing read is available, so nothing can be inferred about Reddit sentiment.

2) CROSS-SOURCE DIVERGENCES AND ALIGNMENTS

News and StockTwits align: both react positively to the Ophir sale, and neither source contains a MKSI-specific bearish voice. The main tension is between deal and valuation positives and sector context. Pre-deal retail chatter (10-16) was uncertain about a bottom, and the semis group was losing relative strength after the MU miss. The hammer-pattern and 60% upside headlines fit a stock that had sold off and is being framed as a rebound candidate. There is no sharp news-versus-retail divergence. Event versus opinion: the divestiture terms are a verified event, while most StockTwits content is unlabeled opinion or relay from a tiny sample. The absence of bearish tags should not be read as strong conviction, and 18% bullish is far from the over-extension zone.

3) DOMINANT NARRATIVE THEMES

Portfolio pruning and cash monetization: a $650M all-cash sale at over 18x unit EBITDA for a roughly 4.5% market-cap piece, framed as balance-sheet-positive. The data does not state how proceeds will be used.
Valuation and dip-buying: ~14x forward earnings, ~21x trailing, an 'undervalued' screen, and a 60.28% implied analyst-target upside.
Semiconductor cycle and memory sentiment: the MU miss, SOXX relative weakness, and DRAM architecture-transition equipment demand.
Peer benchmarking against KLAC, AEIS and ROK.

4) CATALYSTS AND RISKS

Catalysts: deal closing and capital allocation of the proceeds (buyback or debt paydown, not specified in the provided data); a technical reversal if the hammer pattern is confirmed; a semis or memory-capex recovery; and long-dated equipment content from new DRAM structures. Risks: continued semiconductor sector relative weakness following the MU earnings miss; deal closing conditions and timing, which are not in the provided data; loss of Ophir's modest EBITDA (under ~$36M); the reliability of analyst price-target upside; and a hammer pattern that needs confirmation. Data limits: Reddit is unavailable, StockTwits is only 11 messages with 2 labeled, news is headlines only, and there is no price-reaction magnitude, volume, analyst rating change, earnings date or guidance in the evidence. Confidence is therefore low. This is a sentiment signal for the trader to weigh alongside fundamentals and technicals, not a price call.

5) KEY SENTIMENT SIGNALS

Signal	Direction	Source	Supporting evidence
Ophir Optics sale to TTM for ~$650M cash	Bullish	News (GlobeNewswire, MT Newswires, Investing.com)	Announced 2026-10-19; MKSI shares reported higher (pre-bell); magnitude not given
Deal valuation	Bullish	StockTwits (@filecrux, @shimblum)	Over 18x unit FY2026 adj. EBITDA; ~4.5% of ~$14.53B market cap; 'cash is king'
Analyst upside	Mildly Bullish	News (Zacks)	60.28% implied upside to targets; treat cautiously
Hammer chart pattern	Mildly Bullish (needs confirmation)	News (Zacks)	Reversal-candidate framing after a decline
Retail tags	Mildly Bullish (thin sample)	StockTwits	2 Bullish (18%), 0 Bearish, 9 unlabeled of 11; one bullish tag is about TTMI
Valuation screens	Mildly Bullish	StockTwits (@Tickrtrends, @shimblum)	Undervalued screen; ~21x trailing P/E; ~14x forward earnings
Dip-buying vs. bottom uncertainty	Mixed	StockTwits (@shimblum, @MostHated)	'Where is the bottom?' then 'buying here' on 10-16
Semis relative weakness	Bearish (sector)	StockTwits (@eWhispers)	Largest relative-strength drop in SOXX over two weeks since the MU miss
DRAM architecture equipment content	Mildly Bullish (long-dated)	StockTwits (@Techdamentals)	Vacuum and flow-control subsystems underpin process changes; multi-year development
Reddit	No signal	Reddit	Skipped by config; no data

News Analyst¶

MKSI (MKS Inc.) – Weekly News and Macro Report, 14–21 Oct 2026¶

Data coverage¶

FRED macro data was unavailable. I tried the fed funds rate, 10-year yield, CPI, unemployment, VIX and yield curve, then retried with raw series IDs (DFF, DGS10). Every call failed. I have no verified readings for rates, inflation, labor or volatility, and I haven't estimated any.
The news tools returned headlines and links only, with no article text. I can report what the headlines say. I can't report MKSI's share price, deal terms beyond the headline, analyst targets or guidance numbers.
Prediction markets worked for the Fed, recession and tariffs. There is no market for semiconductor export controls.

1. Company news: MKSI¶

Ophir Optics sale to TTM Technologies (about $650M, announced this week) - Several outlets covered it: GlobeNewswire (both companies' releases), MT Newswires, Investing.com and StockStory. - Headlines say MKSI shares rose pre-market on the news. TTM was also reported "trading up". - Ophir is MKS's infrared optics business. The sale continues a portfolio-pruning story, which trims non-core photonics exposure. - From my background knowledge, not the tools: MKS took on significant debt for the Atotech acquisition. A $650M cash inflow could therefore help deleveraging or buybacks. The headlines don't say how the proceeds will be used, so check the press release for this and for the expected closing date and any dilution to earnings.

Q3 2026 earnings - MKS has announced its Q3 2026 earnings conference call. The tool output didn't include the date. - Historically MKS reports in early November, but I couldn't confirm that. Verify the date. It is the main scheduled catalyst. - Management's commentary on the divestiture, semiconductor WFE (wafer fabrication equipment) demand and its Materials Solutions (Atotech) segment will matter.

Sentiment and valuation headlines (Zacks, Simply Wall St., Trefis) - "Wall Street Analysts Think MKS Could Surge 60.28%" (Zacks). This points to a large gap between the consensus target and the price. Sell-side targets are often stale, so treat it as a weak signal. - "MKS Forms Hammer Chart Pattern: Time for Bottom Fishing?" (Zacks). This is a technical reversal signal and implies the stock had been falling. Hammers need confirmation. - "MKS (MKSI) Dropped, So What Is Driving Attention Now?" (Simply Wall St.). This confirms a recent pullback, but the reason isn't in the headline. - "Can MKS Cash Flow Support Its Current Share Price?" (Simply Wall St.). Cash-flow quality is being questioned. - "MKSI vs. ROK: Which Is the Better Value Option?" (Zacks).

Peer and sector read-through - Zacks ran "AEIS Rides on Strong Semiconductor Growth: Can It Beat KLAC and MKSI?" and "Advanced Energy Soars 40% YTD". Advanced Energy (AEIS) is a direct power-subsystem competitor. - Trefis ran several KLA pieces, including "Management Guided Higher For KLA Stock". KLA is a WFE bellwether, and the headlines suggest a constructive tone. - Coherent (a photonics peer) is getting heavy coverage, which suggests investor interest in photonics and AI-optics names. - Read-through: the sector is strong and AEIS is up about 40% YTD. MKSI appears to be lagging peers, which is consistent with the "dropped" and "hammer" headlines.

2. Global and market backdrop¶

Risk appetite was constructive. Nasdaq and S&P futures rose after a "blowout quarter" from SpaceX, which lifted AI and chip stocks (Stocktwits headlines, with SMCI named). This favors semiconductor-linked names.
Earnings season is under way. Meta, Tesla, IBM and Netflix are reporting. MT Newswires described tech as "mixed" on Tuesday afternoon (20 Oct).
AI and compute capex remains the dominant theme. IBM's AI inference launches and the focus on AI infrastructure ("Price of the Watt") keep data-center demand in focus. This is a tailwind for MKSI's end markets.
Commodities: gold futures edged up and oil slipped (WSJ), with no figures given.
Quantum stocks (Rigetti, IonQ, QBTS) were weak, with IonQ described as "down by half in a year". That points to selectivity in speculative tech.

3. Prediction markets (Polymarket)¶

Fed, October meeting (resolves 29 Oct) - No change: 86% ($15.3M volume), up 18pp in a week. - 25bp hike: 12% ($12.0M volume), down 18pp in a week. By simple arithmetic, hike odds were around 30% a week ago. - 25bp cut or larger: about 0%.

Fed, full year - No Fed cuts in 2026: 97% ($9.0M volume). - The market sees no easing this year, and hike risk has not been fully removed.

Recession - US recession by end of 2026: 8% ($2.3M volume). - UK: 6% and Japan: 4%, both very thin markets.

Tariffs - US–Canada tariff-lowering agreement by 31 Oct: 5%. - Same agreement by 31 Dec: 40%. - Section 232 tariffs on copper cable by end-2026: 27%, down 17.5pp in a week. The markets are thin (about $9K volume). - These are low-liquidity, indirect signals for MKSI.

Semiconductor export controls on China - No market exists. I couldn't quantify this risk, which is relevant to WFE suppliers.

4. Implications for MKSI¶

The Ophir sale is a mildly positive, company-specific catalyst. It simplifies the portfolio and brings in cash. Details on use of proceeds, the earnings impact and the timeline are not yet confirmed.
The sector is strong and MKSI looks like a laggard. Peers AEIS and KLA have strong narratives. A laggard can catch up if earnings confirm WFE strength, or the lag can reflect company-specific problems, such as cash flow or the Materials Solutions segment. Earnings should settle which.
Rates are a headwind but are priced. Markets expect a hold on 28–29 Oct, with no cuts this year and some residual hike risk. This is a "higher for longer" regime, which is unfriendly to leveraged, cyclical names. MKSI is a cyclical with meaningful debt (background knowledge). The drop in hike odds this week is mildly supportive.
Recession risk is low at 8%. That supports capex-cycle cyclicals.
Key events to watch:
the FOMC decision (28–29 Oct)
MKSI Q3 earnings (date to be confirmed)
read-throughs from Lam, KLA, AMAT and ASML reports
any change in China export-control policy

5. Caveats¶

No verified numbers for rates, inflation, unemployment, yields or VIX.
No MKSI price, volume, technical levels or analyst target values.
The news items are headlines only. The Ophir deal terms beyond "$650M" and the "shares rise" reaction are unverified, as is the reason for the recent drop.
The prediction-market probabilities are crowd-priced odds, not forecasts.

Summary table¶

Category	Item	Detail / Evidence	Implication for MKSI
Company catalyst	Ophir Optics sale to TTM Technologies	About $650M. Shares rose pre-market per MT Newswires and Investing.com	Mildly positive: portfolio simplification and cash. Check use of proceeds and closing date
Company catalyst	Q3 2026 earnings call	Announced via GlobeNewswire. Date not in the tool output	Main scheduled catalyst. Confirm the date
Sentiment	Zacks "could surge 60.28%"	Implies a large gap to the consensus target	Weak or stale signal. Don't rely on it alone
Technical	"Hammer" candlestick (Zacks)	Possible bottoming signal after a decline	Needs confirmation. No price data to verify
Sentiment	"MKSI dropped" and cash-flow questions (Simply Wall St.)	Recent pullback, cash-flow durability questioned	Risk: possible company-specific weakness
Peers	AEIS up about 40% YTD, KLA guided higher	Strong semiconductor and WFE read-through	Sector tailwind, MKSI appears to lag
Market backdrop	Chip rally on SpaceX and AI earnings	Futures up, tech mixed on Tuesday	Constructive for semis, earnings-season volatility
Fed (Oct)	Hold 86%, hike 12%, cut about 0%	Hike odds down 18pp in a week	Hold expected. Residual hawkish tail
Fed (2026)	No cuts in 2026: 97%	$9.0M volume	Higher-for-longer. Headwind for leveraged cyclicals
Recession	US recession by end-2026: 8%	$2.3M volume	Low risk, supports capex cycle
Tariffs	US–Canada deal by Dec: 40%. Copper cable Sec. 232: 27%	Thin volumes	Minor, indirect
Export controls	No prediction market	No data	Unquantified risk. Watch for policy news
Macro data (FRED)	Rates, CPI, unemployment, VIX, yield curve	Unavailable after retries	No verified macro readings

Fundamentals Analyst¶

MKSI (MKS Inc.) Fundamental Report¶

As of 2026-10-21 | Sector: Technology | Industry: Scientific & Technical Instruments | Exchange: NMS

1. Summary¶

Earnings inflection: Q2 FY26 (quarter ended 2026-06-30) was a breakout quarter. Revenue was $1,248M, up 28% YoY. GAAP net income was $175M, up 182% YoY. GAAP EPS was $2.41, against $0.92 a year earlier.
Share price: The stock is well off its highs. The tool does not quote a price, but the ratios imply about $215. That is about 52% below the 52-week high of $447.62, and below both the 50-day average ($262.91) and the 200-day average ($277.22).
Leverage: The company is highly leveraged (debt/equity 1.40x). Current liabilities jumped by about $1.4B in Q1 FY26. That cut the current ratio from about 2.7x to 1.1x, and the cause is unexplained.
Insiders: Insiders have been consistent net sellers (about $43M since February 2026) and there were no open-market purchases in the data. Nothing has been filed in the past week. The latest transaction is a routine 300-share director sale on 2026-09-01.

2. Valuation and Market Data (from `get_fundamentals`)¶

Metric	Value	Comment
Market cap	$14.57B	About 67.6M shares
Implied price	About $215.5	Derived: P/E 34.26 × EPS 6.29 and P/B 4.876 × book value 44.20 both give about $215.5
P/E (TTM)	34.3	GAAP, depressed by earlier weak quarters
Forward P/E	12.26	Forward EPS $17.58
PEG	1.32
Price/Book	4.88	Book value/share $44.20
Beta	2.03	Very high volatility
52-week range	$130.72 – $447.62	Price is about 65% above the low and 52% below the high
Dividend yield	0.47%	Token dividend
Revenue TTM	$4.347B
Gross profit	$2.041B	About 46.9% gross margin
EBITDA	$1.057B	About 24.3% margin
Net income	$439M	10.1% net margin
Operating margin	20.6%	Latest quarter
ROE / ROA	15.8% / 5.0%
Free cash flow	$480M	About 3.3% FCF yield on market cap
Debt/equity	140%	Implied debt about $4.19B
Current ratio	1.144	Matches the Q2 FY26 balance sheet (2,774 / 2,424)

Derived estimates (my calculations, not tool outputs): - Net debt is about $3.7B (debt $4.19B less cash $454M). That is about 3.5x TTM EBITDA. - Enterprise value is about $18.3B, or about 17x EV/EBITDA and about 4.2x EV/sales. - Forward vs. trailing EPS: The $17.58 forward EPS compares with $6.29 TTM GAAP EPS. The forward figure is very likely a non-GAAP or consensus measure, so the 12.3x forward P/E is not comparable to the 34.3x trailing P/E. Annualizing the Q2 GAAP EPS of $2.41 gives about $9.6.

3. Income Statement Trends (quarterly, USD millions)¶

Quarter	Revenue	Gross profit	GM %	Op. income	Op. margin	Net income	Diluted EPS
Q1 FY25 (Mar-25)	936	444	47.4%	111	11.9%	52	0.77
Q2 FY25 (Jun-25)	973	453	46.6%	135	13.9%	62	0.92
Q3 FY25 (Sep-25)	988	461	46.7%	138	14.0%	74	1.10
Q4 FY25 (Dec-25)	not in tool output (about 1,033 implied)	–	–	–	–	about 106 implied	about 1.60 implied
Q1 FY26 (Mar-26)	1,078	507	47.0%	149	13.8%	84	1.18
Q2 FY26 (Jun-26)	1,248	595	47.7%	251	20.1%	175	2.41

The implied Q4 FY25 figures are the TTM totals minus the three reported quarters, so treat them as approximate.

Key observations: - Revenue growth is accelerating. YoY growth was about +8% in Q1 FY25, +10% in Q2 FY25, +10% in Q3 FY25, +15% in Q1 FY26 and +28% in Q2 FY26. Sequential growth in Q2 FY26 was +15.8%. - First-half comparison: H1 FY26 revenue was $2,326M against $1,909M in H1 FY25 (+22%). H1 net income was $259M against $114M (+127%). - Margins: Gross margin is stable at 46–48%, so the profit surge is mostly operating leverage. Operating expenses (gross profit minus operating income) were about $344M in Q2 FY26 against $358M in Q1 FY26, even with revenue up $170M. The QoQ operating income increment (+$102M on +$170M revenue) is about 60%. - Caveat: A 20% operating margin against about 14% for the prior six quarters should be checked for one-offs, such as lower restructuring or deal costs, or a gain. The tool does not itemize these. - Long-term history: - Revenue grew from about $76M per quarter in 2009 to about $1.25B now. - Step-ups in assets around 2016, 2019 and 2022 match the Newport, ESI and Atotech acquisitions. - The 2023 quarter with a $1.77B net loss (EPS −$26.47, operating income −$1,696M) was a large goodwill impairment. Equity fell from about $4.45B to $2.50B in the same period. - Data caveats: Q4 quarters are missing from the quarterly income statement, and cost of revenue is blank after 2022. Some quarter labels in the 2022–2023 stretch may be misaligned, so I relied mainly on the recent periods.

4. Balance Sheet (USD millions)¶

Date	Total assets	Cash	Current assets	Current liabilities	Total liabilities	Equity
2025-06-30	8,826	498	2,484	832	6,273	2,553
2025-09-30	8,777	413	2,536	886	6,177	2,600
2025-12-31	8,796	418	2,510	927	6,077	2,719
2026-03-31	8,728	463	2,545	2,291	5,917	2,811
2026-06-30	8,941	454	2,774	2,424	5,953	2,988

Current liabilities jumped about $1.36B in Q1 FY26 (927 to 2,291), while total liabilities fell slightly (6,077 to 5,917). That points to a reclassification of existing long-term debt to current, not new borrowing. Possible causes are a nearing maturity, a convertible becoming convertible, or a covenant issue. The tool provides no debt schedule, so the cause is unconfirmed.
Why it matters: If it is a maturity, the company needs to refinance or repay a large amount within 12 months. That is a key item to check in the 10-Q. The current ratio fell from about 2.7x (Dec-25) to about 1.1x.
Equity has risen about 17% over the last four quarters, from retained earnings, and book value per share is $44.20. Equity is about 33% of total assets, and most of the asset base is acquisition-related.
Dilution check: Net income divided by diluted EPS implies about 71–73M diluted shares in H1 FY26, against about 67M in 2025. Book value implies about 67.6M shares outstanding. This may be rounding or dilutive securities. It is worth confirming, especially given the current-liability change.

5. Cash Flow (USD millions, year-to-date figures)¶

Period	Operating CF	Capex	FCF (OCF − capex)	Investing CF	Financing CF
Q1 FY25	141	18	123	−18	−180
6M FY25	306	47	259	−45	−309
9M FY25	503	98	405	−96	−437
Q1 FY26	53	25	28	−25	−137
6M FY26	296	79	217	−80	−285

H1 FY26 FCF was about $217M, down about 16% from H1 FY25's $259M despite much higher earnings. Q1 FY26 operating cash flow was weak at $53M, and Q2 recovered to about $243M (implied), against about $165M in Q2 FY25.
Capex is ramping. H1 FY26 was $79M, up about 68% YoY, and Q2 alone was about $54M. This suggests a capacity build, consistent with the demand pickup.
Financing outflows have been large, about $285M in H1 FY26. That is consistent with debt paydown, dividends and buybacks, but the tool does not break them out.
Reconciliation gap: H1 FY26 operating, investing and financing flows sum to about −$69M, yet cash rose from $418M to $454M. FX or restricted cash may explain part of it, but I can't confirm that.
TTM FCF is $480M, about 1.09x net income, so earnings are cash-backed over the full year.

6. Insider Transactions¶

The tool shows no filings in the past week. The latest is a director's 300-share sale on 2026-09-01. Insiders are probably in the pre-earnings blackout, since Q3 FY26 results are typically due in early November. I didn't confirm that date.

Open-market sales: - May 11 – Sep 1, 2026: 18 sales totaling about $25.0M (about 78,000 shares) at roughly $251–$347. - Feb 20 – Mar 12, 2026: 13 sales totaling about $18.3M at roughly $214–$261. - Purchases: There are no open-market buys anywhere in the data (Nov 2024 – Sep 2026).

Notable sellers: - CEO John Lee: - 30,000 shares on Feb 20 (about $256–260, $7.7M). - 10,000 shares on May 22 ($315.48, $3.15M). - 10,000 shares on Aug 14 ($302.01, $3.02M). - Total: about 50,000 shares and about $13.9M in 2026. - He also had a 69,889-share transaction on 2026-02-17 with no price. This is likely a vesting or tax-withholding event, but it is unclassified in the tool. - CFO R. Mayampurath: 8,810 shares on May 22 at $315.48 (about $2.8M). The identical price to the CEO's sale suggests a coordinated or tax-related sale. - COO James Schreiner: Sold in Feb ($1.05M), June ($1.46M across two sales) and earlier. These are recurring sales. - Director Gerard Colella (indirect): Sold 20,000 shares in Feb (about $5.1M) and 20,000 in May (about $6.7M, the largest single sale), after 8,000 in Feb 2025. - Routine small sales: Directors Mora and Moloney sell about 300 shares at regular intervals. These look pre-scheduled and carry little signal.

Interpretation: - Selling is broad (CEO, CFO, COO, general counsel, multiple directors). Most of it came during the rally from about $80–100 in mid-2025 to the $300s in 2026. - Prices realized ($251–$347) are above today's implied $215. No sales appear near the $447 high, so that peak likely fell in a period when insiders weren't trading. - Heavy insider selling after a 3x+ rally is common and is not necessarily bearish. The absence of buying even after a roughly 50% drawdown from the high is notable, though. It could also reflect the blackout period.

7. Risks and Strengths¶

Strengths: - Revenue and earnings are accelerating sharply. Q2 FY26 shows strong operating leverage, with gross margin stable near 47%. - FCF is solid at $480M TTM, and the company paid a dividend. - Book value is rising steadily. - The forward P/E of about 12x looks cheap if the forward EPS is achievable.

Risks: - Leverage and refinancing: Debt is about $4.2B with a 1.4x debt/equity ratio. Current liabilities of $2.4B almost equal current assets, so the current-liability spike needs an explanation. - Volatility: Beta is 2.0 and the stock fell about 52% from its high. A semiconductor or industrial capex cycle can reverse quickly, and a roughly 20% operating margin may be near cyclical peak. - Earnings quality: The trailing P/E of 34x on GAAP earnings and the gap between $17.58 forward EPS and $9.6 annualized GAAP EPS both depend on non-GAAP adjustments. - Impairment history: The $1.8B goodwill impairment in 2023 shows acquisition risk. Goodwill and intangibles remain a large share of assets. - Insider sentiment: Net selling and no buying. - Cash conversion: H1 FY26 FCF fell YoY while capex is rising.

8. Items to Verify (outside these tools' scope)¶

What debt was reclassified to current in Q1 FY26, and its maturity or refinancing plan.
A GAAP-to-non-GAAP EPS reconciliation, and the source of the $17.58 forward EPS.
One-time items in Q2 FY26 operating income.
The Q3 FY26 earnings date and guidance (expected early November).
The cause of the ~$80M+ cash-flow/cash reconciliation gap, and any dilutive securities.
What drove the decline from the $447 high to about $215, such as guidance, a sector sell-off or a debt concern.

9. Summary Table¶

Category	Key Point	Data	Implication for Traders
Identity	MKS Inc. (MKSI), NMS, Technology / Scientific & Technical Instruments	–	–
Price context	Implied about $215.5, with market cap $14.57B	52-week range $130.72–$447.62; 50-day average $262.91; 200-day average $277.22	Down about 52% from the high and below both moving averages
Volatility	Beta 2.03	–	Large swings are likely, so size positions accordingly
Valuation	P/E 34.3 (GAAP TTM), forward P/E 12.3, PEG 1.32, P/B 4.88	Forward EPS $17.58 against TTM EPS $6.29	Forward P/E is likely on non-GAAP earnings, so verify the basis
Growth	Q2 FY26 revenue $1,248M	+28% YoY, +15.8% QoQ	Clear acceleration
Profitability	Q2 FY26 operating margin 20.1% (against about 14% before); gross margin 47.7%	Net income $175M; EPS $2.41	Strong operating leverage, but check for one-offs
TTM profitability	Revenue $4.35B, EBITDA $1.06B (24%), net margin 10.1%	ROE 15.8%, ROA 5.0%	Decent returns, held back by leverage and impairments
Cash flow	TTM FCF $480M (about 3.3% yield); H1 FY26 FCF about $217M, down about 16% YoY	H1 capex $79M (+68%)	Earnings are cash-backed, but Q1 was weak and capex is rising
Leverage	Debt/equity 1.40x; net debt about $3.7B (about 3.5x EBITDA)	Equity $2,988M; cash $454M	Significant financial risk
Liquidity	Current ratio 1.14, down from about 2.7	Current liabilities $927M → $2,291M in Q1 FY26	Likely debt reclassification; a key item to verify
Balance sheet history	$1.77B net loss in 2023 from a goodwill impairment	Equity $4.45B → $2.50B	Acquisition and impairment risk remains
Insider activity	No filings in the past week; latest is a 300-share director sale on 2026-09-01	About $25.0M sold May–Sep 2026 and $18.3M in Feb–Mar 2026; no buys	Net selling with no insider buying
Key insiders	CEO sold about 50,000 shares (about $13.9M) in 2026; CFO, COO and directors also sold	Colella (indirect) sold 20,000 shares each in Feb and May	Sales were at $250–$347, above the current price
Data gaps	Q4 columns are missing from the income and cash flow statements; no debt, goodwill or share-count detail	–	Cross-check with SEC filings
Catalysts / watch	Q3 FY26 earnings (expected early November), debt refinancing, guidance, non-GAAP reconciliation	–	The outcome will confirm or challenge the earnings inflection

II. Research Team Decision¶

Bull Researcher¶

Bull Analyst: # Bull Case for MKSI (MKS Inc.), $215.51 as of 2026-10-21

The bear will open with the chart: down 51.5% from the June peak, below every moving average, all three SuperTrends pointing down. I'll agree with that, because it's accurate. My argument is that the stock has fallen 51% while the business has been getting better, and that gap is the opportunity.

1. Earnings power: the business just inflected¶

Q2 FY26 revenue was $1,248M, up 28% YoY and 15.8% sequentially. Growth has accelerated every period: +10%, +10%, +15%, then +28%.
Operating margin went from 13.8% to 20.1% in one quarter. Gross margin was steady at about 47%, so this wasn't pricing or mix. Opex actually fell, from about $358M to $344M, while revenue rose $170M. About 60% of the incremental revenue dropped to operating income. That is operating leverage.
GAAP EPS was $2.41, against $0.92 a year earlier. H1 net income was up 127%.
Capex is up 68% YoY in H1. Management is building capacity because it sees demand.
TTM free cash flow is $480M, or 1.09x net income. Earnings are converting to cash.

The stock was $133 a year ago and $444 in June. The market overshot both ways. Now it is pricing a company whose earnings just stepped up as if that step were a mistake.

2. Valuation: cheap even on the conservative math¶

The forward P/E is 12.3x on $17.58 forward EPS. The bear will say that figure is probably non-GAAP, and I agree it likely is. So take the harsher view and annualize Q2 GAAP EPS of $2.41. That is about $9.60, or roughly 22x for a company growing revenue 28% with a PEG of 1.32. From general knowledge rather than the tools, MKS carries heavy acquisition-related amortization from Atotech and Newport, which is the usual source of the GAAP/non-GAAP gap. I'd still ask for the reconciliation, but the stock is not expensive on either basis.

Peers support this. AEIS is up about 40% YTD and KLA has guided higher. MKSI is the laggard in a strong group, which leaves room for it to catch up. Zacks puts the implied upside to consensus targets at 60% (about $345). Targets can be stale, so I treat that as a footnote, not evidence.

3. The Ophir sale reduces the balance-sheet risk¶

The $650M cash sale to TTM is about 4.5% of market cap, at over 18x the unit's projected FY26 adjusted EBITDA (under about $36M). My rough math, before taxes and fees, takes net debt/EBITDA from about 3.5x to about 3.0x. It also sharpens the portfolio. The market gave it a shrug, since the price was 214.83 before and 215.51 now, so I'm not claiming it is the thesis. It is a deleveraging step, and that addresses the bear's best argument.

4. The setup is washed out¶

RSI is 30.6 (27.1 low on 10/20), with a completed daily TD-9 buy setup.
Price sits at the lower Bollinger Band (204.60), and Zacks flagged a hammer.
Four closes between 211 and 216 show selling pausing, and the MACD histogram is narrowing (-5.61 to -5.15).
The last two tests of this zone, 3/9 at 200 and 3/30 at 210, were followed by rebounds.
Macro is supportive: recession odds are 8%, the Fed is 86% priced for a hold, and hike odds fell 18 points this week.
With a beta of 2.0, a stock that overshoots down can also snap back sharply.

5. Where I expect the bear to push¶

"The trend is down with ADX at 45." True, and I won't call the chart bullish. The weekly and monthly SuperTrends are down, and a daily TD-9 doesn't override that. But a 51% drawdown with accelerating earnings and a 12x forward multiple is a valuation reset, not a business collapse. The evidence I'd need for that, such as a guidance cut or a margin break, is absent from every source here.

"Leverage, and current liabilities jumped $1.36B." This is the strongest bear point and I'll concede it needs checking in the 10-Q. But total liabilities fell over the same period (6,077 to 5,917), so this looks like existing debt reclassified as current, not new borrowing. We have $480M of TTM FCF, $454M of cash and now $650M incoming from Ophir. I'd call it a refinancing question to watch, not a sign of distress.

"Insiders are selling." They are, but the sales were at $251–$347, above today's price, and they came after a move from the $80–100s to the $300s. That is diversification after a 3x run, and it is consistent with routine selling. I'll grant the absence of any buying. Q3 earnings should come in early November, and the blackout may explain the silence.

"20% margins are peak." Possibly, and I'd want to check Q2 for one-offs. But gross margin held, opex fell, and revenue is growing 28%. That looks like volume leverage, not a one-time gain.

6. What would prove me wrong¶

A close below 205.62 or the 204.60 band. That opens 200.16 and a z-score near -2.
A weak Q3 print or guidance that confirms the Q2 margin was a peak.
A debt refinancing on bad terms.

Confirmation on the upside is a close back above the 10 EMA (about 231), then the 249 daily SuperTrend flip. Given the 5.7% ATR, I'd size accordingly.

My question for the bear¶

If MKSI's fundamentals deteriorated, I'd expect margins, growth or cash flow to show it. Instead they all improved, and only the price fell. What specific evidence do you have that Q2 was the peak, and what multiple is a 28%-growth, 47%-gross-margin business worth if the answer is "not yet"? Bull Analyst: # Bull Rebuttal: MKSI at $215.51 (2026-10-21)

You made several good points, so I'll start with what I'm giving up.

What I concede¶

Insiders. Your correction holds. The Feb-Mar sales ($18.3M) went at $214-261, which straddles today's price. "Sold above here" is only true of the May-Sep sales.
"Laggard." The tools have no YTD figure for MKSI. I'm withdrawing the word.
The 12.3x forward P/E. The $17.58 is unreconciled, so I won't build on it.
Verified GAAP multiples aren't cheap. 30-34x is right.
My invalidation level. $205.62 is inside one ATR. I replace it in section 7.
Share count. Q2 implies 72.6M diluted shares ($175M / $2.41) against about 67.6M outstanding. Nothing in the tools explains the 5M gap. It's a real flag.

1. The net-income step is mostly arithmetic¶

You noted that net income rose 108% against 68% for operating income, and suspected a below-the-line gift. A simpler explanation fits: a fixed cost below the operating line.

Solving Q1 and Q2 for a fixed charge and a tax rate gives about $55M a quarter and about 11%. That is roughly 5% interest on the $4.2B of debt, though the tools don't itemize it. I then tested it on three quarters it wasn't fitted to:

Quarter	Predicted NI	Actual NI
Q1 FY25	$50M	$52M
Q2 FY25	$71M	$62M
Q3 FY25	$74M	$74M

It's a two-parameter fit and not a reported breakdown, but nothing exotic is needed to explain Q2. Financial leverage on fixed interest widens net income relative to operating income. I'll grant that it cuts both ways, which I use in section 2.

2. Your give-back scenario is already close to the price¶

Take your case: Q3 revenue down 10% to about $1,123M. That still exceeds Q1's $1,078M. Over a longer baseline the incremental margin is lower than my 60% quarter-on-quarter figure. From Q3 FY25 to Q2 FY26, revenue rose $260M and operating income rose $113M, so the incremental margin is 43%. Opex rose only $21M (6.5%) on 26% more revenue, which is operating leverage, not an elevated Q1 flattering the comparison.

Using the fit above, about 72.6M diluted shares, and D&A of roughly $92M a quarter (my inference from TTM EBITDA less approximate operating income):

Scenario	Quarterly op. income	GAAP EPS (annualized)	GAAP P/E	EV/EBITDA
Q2 holds	$251M	$2.41 ($9.60)	22x	~13.4x
Your 10% give-back	$176-197M	$1.49-1.74 ($6.0-7.0)	31-36x	~16-17x
Revenue +8% sequentially (not my base case)	~$294M	~$2.94 ($11.7)	~18x	~12x

If the 10% give-back happens, 16-17x EBITDA is roughly where the stock trades on TTM numbers today (17x). It's fair there, not broken. The diluted-share question could add at most about 0.8x to the EV/EBITDA column, and less if the extra shares come from a convertible already counted in debt. GAAP P/E overstates the multiple because of non-cash acquisition amortization, which is general knowledge and not in the tools. A retail post puts trailing P/E at about 21x, which implies about $10 of trailing non-GAAP EPS and a GAAP-to-non-GAAP gap of about $4. That is low-confidence, but it is the right order of magnitude.

The price anchor matters too. The stock closed at $210.12 on 3/30. Trailing GAAP EPS then was about $4.39 (from the tools' quarterly data), or roughly 48x. Today the price is the same and TTM EPS is $6.29, so 34x. Quarterly EPS has gone from $1.18-1.60 to $2.41. At $215 you get paid in full if Q2 mostly holds, and you roughly break even if it half-reverses.

3. Pull-ins, capex and cash flow¶

Pull-ins. I can't rule them out, and you can't confirm them. Pull-ins are usually industry-wide, and the headline this week is that KLA guided higher. That is headline-only evidence, but it points the wrong way for your thesis.
Capex. The 68% growth is off a small base. H1 capex was 3.4% of revenue against 2.5% a year earlier. That is a modest step up, not an overbuild.
FCF. You're right that H1 was down 16%, but that average hides the quarterly pattern. Q1 was weak ($28M). Q2 FCF was about $189M against $136M a year ago, up 39%, and 1.08x net income. The quarter that carried the earnings step converted to cash.

4. Liquidity¶

Your $1.58B vs $1.36B arithmetic assumes the reclassified debt must be repaid from cash. A reclassification means it needs refinancing or repayment, which are different things.

Strip out the roughly $1.36B jump and the current ratio is about 2.6x, not 1.14x. This assumes the whole jump is the reclassified debt.
The reclass appears on the 3/31 balance sheet. The stock closed at 229 the next day and reached 444 by 6/30. I don't have the 10-Q filing date, but the market had a full quarter with the reclass visible and paid roughly double. It can't be what changed in October.
On rates, the market prices a hold, not a shock. The roughly 5% implied cost on existing debt is already at today's rates. Hike odds fell 18 points this week, and your 12% hike tail is the smaller number.
If the share-count gap is a convertible, it fits the reclass. The dilution would already be inside the $2.41, and it would be a share-settlement question as much as a cash one.
Ophir's $650M is about 15% of the debt. At a roughly 5% interest cost that saves about $34M a year, against under $36M of lost EBITDA, with the lost earnings lower after D&A and tax. On TTM EBITDA, net leverage goes from about 3.5x to about 3.0x. Use of proceeds is still unstated, and so are fees and closing conditions.

5. October¶

I agree 25% in two weeks deserves respect. Two observations:

The 281 to 211 leg gave back most of a 23% squeeze from 228 on 9/15 to 281 on 10/6. The drop from the 9/14 close of 267 is 19% over five weeks.
The only attributable candidate in the evidence is sector-wide. SOXX posted its largest relative-strength drop in two weeks after an MU earnings miss, and equity futures rose on AI enthusiasm during that window. The source is one retail post, so I treat it as a candidate and not a conclusion. With a beta of 2.0, a sector de-rating hits MKSI hard. It still is not evidence that Q2 was a peak.

I'll also nitpick the "failing rallies": highs of 329, 270 and 286 are not a strict lower-high sequence.

6. Insiders¶

The absence of buying is a constant, not a signal. The data covers Nov 2024 onward, and nobody bought at $80-100 in mid-2025 either, before a 4x move. The Feb-Mar sellers sold at $214-261 before the stock went to 444. If those sales were timing, the timing was wrong. The CEO's sales (Feb 20, May 22, Aug 14) are roughly quarterly and look like a program, though that's an inference. I grant they don't confirm conviction.

7. How I'd actually trade it¶

The 205.62 stop is gone. Here is the replacement:

Sizing: a starter position, not a full one. ATR is 5.7%, and the FOMC (10/28-29) and Q3 earnings both land within about two weeks. A 2x ATR stop is about $24, near $191, so size for that.
Adds: on a close above the 10 EMA (about $231) with volume, and more above 249.15. Waiting for 249 costs about 16%, which is a lot to pay for certainty after a stock has already moved 25% in two weeks in either direction.
Thesis invalidated by: Q3 revenue down more than 10% sequentially, operating margin below about 16%, a guidance cut, a refinancing on bad terms, or a weekly close below the 3/9 low of 200.16.

Your closing point¶

You said my thesis needs Q2 to be the floor. It doesn't. It needs earnings power to settle somewhere above where it was when the stock last traded at $210, and your own give-back case lands there with more revenue and more operating income than Q1. The price already discounts a big reversal, while the evidence you flagged (debt reclass, share count, below-the-line items, the cause of the drop) is checkable within weeks. I'd rather own a small position through that than buy a larger one after a 16% gap. Bull Analyst: # Bull Closing: MKSI at $215.51 (2026-10-21)

You won several of these rounds, so I'll give up what you earned and then argue what's left.

Where you're right¶

My September numbers were wrong. The 9/14 close was 239.27, not 267, and the stock gave back all of the October squeeze, not most of it. I'm withdrawing both.
The sector story is too thin to carry weight. It rests on one StockTwits post, so I'm not using SOXX to explain the drop.
The debt reclass, share count and guide are public already. They're in the May and August filings, so "checkable within weeks" was wrong. Our tools don't have them, but they're knowable now, and reading them comes before sizing.
Your maturity logic sharpens the risk. Current liabilities were $927M at 12/31/25 and $2,291M at 3/31/26. If the reclass is a plain maturity, it falls between January and March 2027, two to five months out. The date will be in the debt note.
Leverage depends on which quarter you believe. Net leverage after Ophir is about 3.3x on a Q1 run-rate, as you say, and about 2.3x on a Q2 run-rate. That is the same Q2 debate again.
Q2's 11% tax rate may be favorable. At 18%, EPS is about $2.21, so I'd haircut Q2.
A stop doesn't protect through a gap. The plan below sizes for the gap instead.

1. Your payoff table needs three fixes¶

You asked for a target and probabilities. First, your table has three problems: one P/E (30x) is applied to every scenario, there's no upside case despite growth accelerating (+10%, +10%, +15%, +28% YoY), and the weights are yours.

Here is a version on EV/EBITDA, which strips out amortization as you noted. It uses diluted shares of 72.6M, which is the conservative count, and net debt of $3.7B. D&A of about $92M a quarter is my inference from TTM EBITDA. Everything here is my estimate, not tool output.

Scenario	My prob.	Qtr op. income	Run-rate EBITDA	EV/EBITDA	Value	vs $215.51
Growth continues (rev +8% seq.)	25%	~$294M	~$1.54B	15x	~$268	+24%
Q2 holds	35%	$251M	~$1.37B	15x	~$232	+8%
Your 10% give-back	25%	~$185M	~$1.11B	16x	~$193	−10%
Full reversal to Q1	15%	$149M	~$0.96B	16x	~$161	−25%

My weights give about $221 (+2%). Your weights (20/30/30/20) give about $213 (−1%), not your −3%.

That is a thin edge from valuation alone, and I'd rather say so. The payoff is roughly symmetric at the extremes (+24% and −25%), so what matters is the odds on the extremes. Each turn of EV/EBITDA on the Q2 run-rate is worth about $19 a share. If Q2 holds and the market pays 18x, which I estimate it did in mid-August, the value is about $289.

2. The decline came after the numbers were public¶

I'll take your inference that the Q2 print was out by the CEO's 8/14 sale at about $302. At that price the stock was about 18x the same annualized Q2 EBITDA, on my diluted-share estimate. It is about 14x now.

The reported numbers haven't changed, and the stock is about 30% lower from 8/14.
Most of that decline came in later discrete legs: 9/14 (−10.5%) and 10/6 to 10/20 (−25%).
That doesn't fit "the market read the filings and rejected them." It paid $302–$329 with the filings in hand.
It also doesn't tell us what changed. You say company-specific or peak fear, and I can't rule that out. That unexplained leg is the real residual risk, and it's why I'm sizing small.
The tape also gaps in both directions: the stock rose 28% in four sessions from 7/29 to 8/4. Price path alone is a noisy read of information.

3. Liquidity is a gating item, not a disproof¶

I can't tell the instrument or the settlement terms. If it's a convertible below its strike, a dilution question becomes a cash question, as you say. General knowledge, not in the tools: refinancing is underwritten on run-rate earnings and cash flow, and Q2's run-rate puts MKSI in a better position than Q1's did. That is a view, not evidence, so I want the debt note.

4. The plan, in order¶

Read the Q2 release and 10-Q first. I need the Q3 guide, the debt instrument, maturity and settlement terms, the diluted share count and the non-GAAP reconciliation.
Pass if any of these show up:
The guide implies revenue down more than about 10% sequentially (below roughly $1.12B).
The guide implies operating margin below about 16%.
There's an unfunded maturity with no refinancing path.
Size for the gap, not the stop. A −30% move (about $150, near my full-reversal value) should cost no more than about 0.5% of capital, which means roughly a 1.5–2% position. The FOMC (10/28–29) and the Q3 print both land inside two weeks.
Add on a close above the 10 EMA (about $231) with volume, and more through 249.15. You're right that this costs 7%, not 16%.

The guide check is worth doing because it moves the odds a lot:

Guide flat-to-up: I'd shift the weights to about 30/45/20/5, which gives about $231 (+7%).
Guide down about 10%: about 0/15/55/30, which gives about $189 (−12%).

Where we've ended up¶

We're no longer arguing cheap versus expensive. The question is whether about 14x EBITDA on a Q2 run-rate, with a time-boxed debt question and an unexplained 30% slide, is adequate pay. You say not until 249. I say yes at starter size once the filings pass the gate, because the same earnings were valued at about 18x in August and nothing in our data has gotten worse since.

My question for you is at what multiple on Q2 run-rate EBITDA you would own it if the Q3 guide holds near $1.2B and the debt note is clean. At 12x the value is about $176, and at 14x it's today's price. If you need 12x, we're about $40 apart, and the guide will show which of us is right. Bull Analyst: # Bull Closing: MKSI at $215.51 (2026-10-21)

You've moved the debate to where it should be, so I'll skip the chart and the sentiment posts and answer the numbers.

What I concede¶

The 20/30/30/20 weights were mine. You used three equal scenarios, so my "−1% on your weights" was my construction.
My gate admits my own give-back case. Revenue of about $1,123M at a 16.5% margin passes a "below $1.12B or below 16%" test, and my table values that case at $193. That's a design error.
Valuation alone is a wash. I'll show the numbers below, but I'm not claiming an edge larger than the error in my inputs.
"Stocks peak before earnings" is the live risk. I can't refute it from these tools. I can only say what would distinguish the two readings.
Reading the guide is homework, not a catalyst. It's public, so no position goes on before I've read it.

1. Your one-turn haircut contradicts your cyclical argument¶

You told me cyclicals look cheapest at the top of the cycle. The corollary is that multiples expand when earnings fall, so the downside cases deserve higher multiples, not lower. Cutting a turn from every scenario penalizes the weak cases twice.

Scenario (weight)	My value	Your −1 turn on all	−1 turn on up-cases only
Growth continues (25%)	$268	$247	$247
Q2 holds (35%)	$232	$214	$214
10% give-back (25%)	$193	$178	$193
Full reversal (15%)	$161	$148	$161
Weighted	$221 (+2%)	$203 (−6%)	$209 (−3%)

The honest range is −6% to +2%, which is zero edge, and I'm not defending a number inside that band. $215 is about 15x my probability-weighted run-rate EBITDA. The market is pricing roughly my distribution at a mid-cycle multiple. The edge isn't in the valuation. It's in whether the two public documents narrow the distribution, which is why I'm gating the trade on them.

My 15% weight on full reversal is a stock at about $161, which is 64% below the $444 peak. From general knowledge, not the tools, semicap downcycles have often run 40–60% peak to trough, so that case is already a severe one. Your equal weights put it at 33%. That probability is the real disagreement, and neither of us can settle it from here.

2. The 26x → 18x → 14x path fits both stories¶

You read a market lowering what it will pay for a run-rate it doesn't trust. I read a momentum multiple unwinding after a 3x run. I also can't date the Q2 print from these tools, and you inferred it from the 8/14 insider sale. So the 26x at $444 was paid on 6/30, possibly before the numbers were public.

Price can't separate these readings, and the Q3 guide, order commentary and debt note can. They're public, so we can read them now. That is also why my "nothing has gotten worse" line was weaker than it sounded. It was a statement about our blind spot, as you said.

3. The corrected gate¶

Buy only if all three hold: 1. The guide implies revenue near $1.2B or better, with operating margin near 18% or better. That is flat or up, not "not down 10%." 2. The debt note shows the maturity is dated and fundable, or already refinanced by a post-6/30 8-K. It should also give the convert terms if the 5M-share gap is one. 3. Ophir proceeds are committed to debt paydown.

If the guide lands in the middle (revenue $1.12–1.2B, margin 16–18%), that's my give-back case, worth about $193. Then I agree with you: the price to pay is $195, not $215. Your 13x run-rate entry and my 16x give-back value are the same number, which is a useful place for two people to land.

If the guide is clean, my weights shift to about $231 (+7%) from $215. A clean guide plus a clean debt note is your own condition for owning it, so you'd buy at $195, and I'd start at $215.

I'm also amending my invalidation line. I wrote that a weekly close below 200.16 invalidates the thesis, and your $195 entry sits below it. With clean filings, a break there means the market is pricing something outside the filings, which is the unexplained-leg risk again. I'd treat it as a review trigger on the starter, not an automatic add. I'm not going to pretend price at 195 is simply a better entry. That is the one place where we'd be buying against the tape.

One other correction to my own plan: on clean-guide weights my EV is about $231, so an add at the 10 EMA has no valuation edge. It's a confirmation add, and I'd size it that way.

4. Your portfolio-impact math¶

You're right that +2% on a 1.5–2% position is 0.04% of capital. The same sizing math caps a −30% gap at about 0.5%. If that isn't worth the effort, it's an opportunity-cost argument, not a valuation argument. The information check costs nothing, and the position only exists if it comes back clean.

Where we've ended up¶

We agree on the process: read the filings first, then act. We agree on one entry, about $195 with a clean gate. The remaining gap is a single decision. With a clean guide and clean debt note, do you buy a starter at $215 or wait for $195 or a $231 reclaim? You'd wait and I'd start, but the gap is about 9% in price on a small position.

Bull verdict: a conditional buy, not a chart trade. If I can't get to the guide and the debt note before the FOMC (10/28–29) and the Q3 print, I have no position. The case for owning MKSI is that the earnings are real and cash-backed (Q2 FCF was 1.08x net income), that it's about 14x run-rate EBITDA (13x on the corrected share count) after a 51% drawdown, and that its biggest risks are checkable.

What proves me wrong: - A guide below $1.2B or margin below 18%, which moves me to your $195. - A maturity inside Q1 2027 with no funding path. - Ophir proceeds that don't reach the debt. - A Q3 print that confirms Q2 as the margin peak. Bull Analyst: # Bull Closing: MKSI at $215.51 (2026-10-21)

We now agree on almost everything except one decision, so I'll take what you've earned, point out where your closing contradicts itself, and say what I'd do.

Where you're right¶

The gate tests the wrong period. The August guide and the 6/30 balance sheet can't explain a 25% drop that happened in October. The document that postdates October is the Q4 guide in the early-November release (date unconfirmed, and assuming MKS guides a quarter ahead, which is general knowledge). I'm moving my decision point accordingly.
The gate's payoff is inside the error bars. On your table, clearing it is worth +1% to +7%, and that doesn't pay for event risk by itself.
No filing refutes "cyclicals peak before earnings." Only the forward guide and customer commentary can.
$195 is a ceiling, not a trigger. I agree.

1. Your price trigger fails your own table¶

Your clean-guide value, with the up-cases-only haircut, is $217. Here is what that implies at your confirmation levels:

Entry	Value	Implied return
$215.51	$217	+1%
$231 (10 EMA)	$217	−6%
$249 (daily SuperTrend flip)	$217	−13%

A close above $231 on volume is a price event, not an information event. The distribution of outcomes is the same, and you've simply paid $15 more for it. Your Q3-print trigger is different, because it narrows the distribution and so can justify a higher price. But the $231 trigger is a momentum purchase, and by your own numbers it costs the entire expected return.

It also collides with your trim advice. You call 228–235 "the natural place to trim" and the zone where a failed bounce becomes your short setup. The same zone can't be where bounces get sold and where they get bought. If 249 is the real confirmation, waiting costs 16%, and "nearly free" no longer applies.

2. Waiting is insurance, and the premium is the gap¶

Waiting for the print means buying after the information arrives, and the gap goes both ways on this tape. It fell 10.5% on 9/14, and it rose 28% in four sessions from 7/29 to 8/4. For a name with a 5.7% ATR, a clean print could gap well past the 7% you're pricing.

That doesn't make waiting wrong. Insurance against a −30% gap can be worth buying, and you're buying it. I'm only objecting to calling it free. I also accept your sizing point. At 1.5–2% of capital, both of our errors are measured in hundredths of a percent, so this is mostly a process disagreement.

3. My amended plan¶

Read the 10-Q now. I want the debt note (maturity, instrument, convert terms), the share count, and the non-GAAP reconciliation. The purpose is to eliminate tails, not to find edge. If the maturity is unfunded with no path, or the share-count gap is unexplained, I have no position.
Cut the pre-print starter to about 1%, and only if step 1 is clean. A −30% gap then costs about 0.3% of capital.
Treat the November Q4 guide as the real test. I also want WFE customer commentary, such as the Lam and KLA reports on the macro watch list, which are public within days.
Add to 2% if the guide holds revenue near $1.2B or better, margin at 18% or better, and Ophir proceeds go to debt.
Cut if the guide lands in the middle, since that is my $193 case.
Exit if it breaks the pass conditions.
A close above the 10 EMA is a confirmation add only. It carries no valuation edge, and I'll size it that way.

4. What's left between us¶

Everything else has converged:

The stock is about 14x Q2 run-rate EBITDA (about 13x if the convert is already in debt) and about 17x TTM.
Net leverage is about 3.5x, or about 3.3x after Ophir on a Q1 run-rate.
The debt date is probably January to March 2027.
Valuation alone is neutral.

Two disagreements remain. First, the odds of a full reversal to Q1 earnings: I say 15%, you say a third, and neither of us can settle that from here. Second, whether to own a small amount through the print. I would, because I'd rather have a small position when the information arrives than watch a 10% gap from the sidelines.

Bull verdict¶

Conditional buy at starter size, filings first, and not a chart trade. The thesis rests on three things:

The earnings are real and cash-backed. Q2 FCF was about 1.08x net income.
The price is about 14x run-rate EBITDA after a 51% drawdown, and the market paid about 18x for the same run-rate in August by my estimate.
The biggest risks are identifiable and mostly dated: the maturity, the share count, and the Q4 guide.

What proves me wrong: - An unfunded maturity inside Q1 2027. - Convert terms that turn a dilution question into a cash question. - A Q4 guide below about $1.2B revenue or about 18% margin, which moves me to your $195. - A Q3 print that reads as the margin peak. - Ophir proceeds that don't reach the debt.

If the guide is clean and the stock gaps to $250, you'll have been right about price discipline and I'll have been right about direction. If the guide disappoints, the starter costs about 0.3% of capital and you'll have been right about the October drop. The guide settles it either way.

Bear Researcher¶

Bear Analyst: # Bear Case for MKSI (MKS Inc.), $215.51 as of 2026-10-21

You conceded the chart, so I'll go after what you think is your strength: that the business is improving and the price is wrong. The data supports a different reading. Q2 is a strong print, but it is the one quarter your whole thesis rests on, and several details look less clean than you've presented them.

1. The market has already seen Q2 and kept selling¶

You say the stock fell 51% while the business improved. The stock peaked at 444 on 6/30, the last day of Q2. It closed at 329 on 8/4. I don't have the report date in the tools, but the CEO's 8/14 sale at $302 suggests the trading window was open, so the results were almost certainly public by then. The stock has dropped about 35% since 8/4, and that is after the $2.41 print. When good news is sold, the market is usually questioning how long it lasts. It is not ignoring it.

Neither of us can explain the October leg, which took the stock from 281 to 211 in two weeks. The news report shows no MKSI-specific negative headline, and the technical and sentiment reports both say they can't attribute the drop. You wrote that evidence of deterioration is "absent from every source here." Those sources are headlines-only and say they can't tell us why the stock fell. Absence of an explanation isn't evidence that nothing is wrong, and 25% in two weeks on 2.5M-share volume deserves more respect.

2. Q2 has quality questions you skipped¶

The revenue step is a discontinuity. Implied sequential growth was +4.6% in Q4 FY25 and +4.4% in Q1 FY26, then +15.8% in Q2. A cyclical equipment supplier that suddenly jumps from 4% to 16% sequentially is the textbook setup for pull-ins and double-ordering. I can't prove that from these tools, but you can't rule it out either.
Not all of the profit surge came from operating leverage. Operating income rose 68% QoQ (149 to 251), but net income rose 108% (84 to 175). Net income as a share of operating income ran 46%, 54%, 56%, then 70%. Something below the operating line, such as tax, interest or other income, helped Q2. You attributed all of it to operations, and the tool output can't confirm that.
Your 60% drop-through works in reverse. If Q3 revenue gives back 10% (about $125M), 60% decremental margin takes about $75M off operating income, back to roughly $175M. Fixed costs mean leverage is symmetric.
Opex "fell" only relative to an elevated Q1. Q1 opex was about $358M, but it was $323M in Q3 FY25, so Q2's $344M is still up $21M from there.
Capex up 68% is also a cycle signal. Adding capacity near a peak is how cyclicals usually get hurt.

3. The valuation isn't "cheap on either basis"¶

Your 22x annualizes the single best quarter in the company's history. On H1 GAAP EPS ($3.59, so about $7.20 annualized), the stock is about 30x. On TTM GAAP ($6.29) it is 34x.

If operating margin only fell halfway back to 17%, which is still above anything in the prior six quarters, annualized GAAP EPS would be roughly $6.50–$8.20. That puts the stock at about 26–33x. This is my arithmetic from the tool data, using Q1 and Q2 net-to-operating conversion as the range.

The 12.3x depends on a $17.58 forward EPS neither of us has reconciled. That is $4.40 per quarter, 82% above Q2's record, and about $8 per share (roughly $550M a year) above annualized GAAP. You say amortization explains the gap, but that's from general knowledge. Stock compensation and restructuring are usually in non-GAAP adjustments too, and those are real costs.

The metrics we can verify aren't cheap: - EV/EBITDA is about 17x. - Market cap to FCF is about 30x, a 3.3% yield. - P/B is 4.9x and PEG is 1.32.

Even if 12x forward is right, a cyclical at 12x peak-ish earnings is fairly priced, not cheap. Cyclicals look cheapest at the top of the cycle.

4. The liquidity math doesn't comfort me¶

You netted $480M of FCF, $454M of cash and $650M from Ophir against the $1.36B reclass (927 to 2,291). That sums to $1.58B, so covering one tranche uses every dollar of cash, a full year of FCF and pre-tax proceeds from a deal that hasn't closed. Cash covers 19% of the $2.42B in current liabilities, and the current ratio is 1.14.

I agree total liabilities fell, so it's probably a reclassification. That is the problem. A large piece of debt matures or becomes callable within 12 months, in a market that prices 97% no cuts in 2026 and a 12% hike chance next week. Refinancing a 3x-levered, beta-2 name in that regime may not be cheap.

One more thing to check. Net income divided by diluted EPS implies about 67M shares through Q3 FY25 but about 71–72M from Q1 FY26, the same quarter the current liabilities jumped. That could be rounding or a coincidence. But if the debt is convertible, the "refinancing question" also has a dilution question attached.

Free cash flow is also softer than you said. H1 FY26 FCF was $217M, down 16% YoY while net income rose 127%, which is 0.84x conversion. The 1.09x TTM figure leans on earlier quarters.

5. Ophir: the market sold the news¶

You conceded the shrug, but it was worse than that. The stock closed at 214.83 on 10/16 and 215.41 on announcement day. It then fell to 211.14 on 10/20 with an intraday low of 205.62, so the pre-market pop faded within a session. By your own math, net leverage only gets to about 3.0x, before taxes and fees, and the use of proceeds isn't stated. At 18x unit EBITDA against MKSI's own roughly 17x EV/EBITDA, it isn't a multiple win either.

6. This isn't washed out¶

RSI and the bands: The technical report says RSI can stay near 30 when ADX is above 40, and ADX is 45. Price can also ride the lower Bollinger Band in a strong downtrend.
TD-9: It is a daily signal. The weekly and monthly counts are only at +3, and a daily 9 doesn't override two bearish higher timeframes.
The base: It is four closes. Today's volume was 717K, so the bar may be incomplete. The hammer needs confirmation.
Z-score: The daily is -1.54, not the -2 extreme.
Rallies are failing: Highs went 329, 270, 286. A rally to the 249 daily SuperTrend flip is about 16%, and the weekly stop is at 319.
The March tests: The technical report calls 3/9 and 3/30 "single instances, not proof." This would be a third test, with the downtrend now established.

Your invalidation level of 205.62 is $9.89 (4.6%) below price, which is less than one ATR ($12.24). Normal daily noise can hit it, so the thesis can't really be tested at that level. A 2x ATR stop is about $24, or roughly 11%.

7. Quick hits¶

Insiders: Some sales were at $214–$261 (Feb–Mar), around today's price, so "they sold above here" isn't the full picture. The CEO sold on 8/14 at $302 with the stock already down about a third. There have been no purchases in 23 months, even at $215. The window was open in August and early September, when the CEO and a director sold, and nobody bought.
"Laggard" vs. AEIS: The tools have no YTD figure for MKSI, so that comparison is a headline inference. If peers are strong and MKSI is down 51%, the cause could be company-specific.
Macro: It isn't clearly supportive. FRED data was unavailable, so we have only prediction markets. The FOMC meeting is 10/28–29 and Q3 earnings are due in early November, both inside a week or two. SOXX also had its largest relative-strength drop in two weeks, and beta of 2 hurts in a weak tape as much as it helps in a bounce.

Your question¶

I don't have to prove Q2 was the peak. Your thesis needs it to be the floor, and the evidence is mixed at best: a discontinuous revenue jump, a net-income step larger than the operating step, falling FCF, rising capex, and a market that has sold the stock 35% since the print was likely public.

As for what a 28%-growth, 47%-gross-margin business is worth if the answer is "not yet": a cyclical with 3x net leverage, a big near-term debt question and a beta of 2 doesn't deserve a growth multiple on one quarter. On verifiable numbers it trades at 34x GAAP, 17x EV/EBITDA and 30x FCF. The reward for being right is unverified. The cost of being wrong includes a downtrend with ADX at 45 and no insider buying.

What would change my mind¶

A 10-Q or call that explains the debt reclass with a funded refinancing.
A GAAP-to-non-GAAP reconciliation that supports the $17.58 forward EPS.
Q2 below-the-line items shown to be recurring.
A Q3 print and guide that hold the 20% margin.
A close above 249.15 on rising volume.

Until then, a bounce here is a trade inside a downtrend and not a thesis. I'd rather wait for evidence than pay 26–34x for a margin that has existed for one quarter. Bear Analyst: # Bear Closing Rebuttal: MKSI at $215.51 (2026-10-21)

You gave up a lot in that rebuttal, and I'll give up some of my own points before showing what's left.

Where I'm giving ground¶

Net income vs. operating income. Your fixed-charge fit ($55M a quarter, 11% tax) is a fair explanation, so I withdraw the suggestion that a below-the-line gift drove Q2. Two cautions remain. The fit misses Q2 FY25 by $9M ($71M predicted vs. $62M actual). An 11% tax rate is also low. At 18%, Q2 EPS is about $2.21, not $2.41.
Capex and Q2 cash flow. Capex at 3.4% of revenue isn't an overbuild, and Q2 FCF of $189M (1.08x net income) was good. I'm dropping both points.
Insiders. Selling after a 3x run and no buying through the whole dataset is a constant, not a signal.
"Lower highs." 286 is above 270, so that was loose. The cleaner evidence is the lows: 255.92, 228.46, 212.35, 205.62.

1. What's left of your thesis is much smaller¶

You opened with "cheap on either basis." You now say the stock is "fair if it half-reverses" and propose a small position. You've conceded 30–34x GAAP, dropped the 12.3x forward P/E, and dropped the Zacks target, and you haven't put a target price in their place. That is a trade on one print, not a valuation case.

2. Your table shows what the stock costs, not what it's worth¶

Your scenario table gives the multiple at today's price. It never gives a value. Here is the payoff at 30x GAAP, the low end of the multiple you conceded, using your EPS figures:

Scenario	Annualized GAAP EPS	Value at 30x	vs. $215.51
Q2 holds	$9.64	$289	+34%
Your 10% give-back	$6.0–7.0	$180–210	−16% to −3%
Full reversal of the Q2 step (Q1 FY26 EPS of $1.18)	$4.72	$142	−34%

Weight the three equally and the expected return is about −3%, for a beta-2.0 stock at roughly 3.5x net leverage. Even if Q2 holds, the stock is at 22x, and getting +30% needs about 29x on what may be peak-cycle margins. Your closing line says that if Q2 "half-reverses," you "roughly break even." That is zero return for a 5.7% daily ATR.

A full reversal is also not exotic. It puts revenue at Q1's $1,078M, which was reported two quarters ago. Sequential drops of that size are common in semiconductor equipment downturns, though that is general knowledge and not from the tools.

On your amortization argument, EV/EBITDA already strips it out, and it is 17x TTM. The 13.4x in your table holds only if Q2 is the permanent run-rate. The 21x trailing P/E is a StockTwits figure you called "the right order of magnitude." The one number we have on a reported basis is 34.3x. Taking untraceable numbers from retail posts is how the 12.3x got into the thesis in the first place.

3. The items you call "checkable within weeks" are already public¶

You list the debt reclass, the share count, the below-the-line items and the non-GAAP reconciliation as things that will resolve soon. They aren't future events. They are in the Q1 and Q2 10-Qs and earnings releases that came out in May and August. MKS also typically guides a quarter ahead (general knowledge, not in the tools), so the Q3 guide was likely given with the Q2 print.

The market has all of that, and neither of us does. The stock is down about 35% from the 8/4 close of $329 with those documents in hand. You propose to size a position first and learn the contents through the earnings reaction. The tools are headline-only, but the answer to that limitation is to read the filings before sizing.

4. Your October explanation doesn't hold up¶

"Gave back most of a 23% squeeze." The run from 228.46 (9/15) to 281.41 (10/6) was about +23%. The 10/20 close of 211.14 is 7.6% below that 9/15 low. The stock gave back all of the squeeze and made a new low.
"19% over five weeks from the 9/14 close of 267." The 9/14 close was 239.27. The 267.31 was the 9/11 close, so the five-week framing includes a −10.5% single-day gap that you smoothed over. The July run had two consecutive days of about −10% (315 to 285 to 257). These are discrete gap legs, not a gradual de-rating.
The sector story. It rests on one StockTwits post about SOXX relative strength. It also sits awkwardly next to your other evidence: KLA guiding higher, AEIS up 40% YTD, and futures rising on AI enthusiasm. If the sector is that strong and MKSI is down 51%, the cause is company-specific or the market is discounting a peak. You can't use sector strength to support demand and sector weakness to explain the drop.
Scale. The stock has lost about $15.5B of market value since 6/30. Ophir's $650M is 4% of that.

5. Liquidity: your three defenses¶

"The market saw the reclass in March and paid double." A risk ignored during a momentum run to $444 isn't a cleared risk. A current classification on 3/31 means the debt is due within 12 months of that date, so by roughly March 2027, about five months out. Current liabilities were still $2.42B on 6/30, so as far as the tools show it hadn't been refinanced when equity was at its most valuable.
The convertible hypothesis. If it's right, share settlement works only while the stock stays above the conversion price. I don't know the strike, and the stock is now below where it was on 3/31, when the reclass appeared. A drifting stock turns a dilution question into a cash question.
The 5% cost of debt. That is a fit parameter, not a coupon. If a large piece is a low-coupon convert or a floating-rate loan, refinancing in a market that prices 97% no cuts in 2026 moves the interest line.

On Ophir, the 3.0x net leverage depends on TTM EBITDA, which includes Q2. On a Q1 run-rate, using your D&A estimate, it is about 3.3x even after the sale. That also assumes the proceeds go to debt, which nothing in the tools says.

6. The trade plan doesn't protect you through the event¶

Your stop is near $191. This stock has had days of −9.6%, −9.7% and −10.5%, and the 2x ATR stop is 11% away. Your invalidation triggers are Q3 revenue down more than 10%, margin below 16%, a guidance cut and a bad refinancing. All of them arrive in a single release, after the FOMC on 10/28–29, and the stock can open below $191 with the stop doing nothing. Holding "through that" is a coin flip on the print, not risk management.

Your argument for not waiting is that confirmation costs 16%. Your own add trigger is the 10 EMA near $231, only about 7% above here, and it is the first level the stock hasn't been under since 10/6. Waiting for it costs 7%, not 16%.

My answer¶

You said the thesis only needs earnings to settle above where they were when the stock last traded at $210. That is necessary, not sufficient. In March the market paid about 44x the Q1 run-rate for an expected upswing. Q2 delivered the upswing, and the stock is back at the same price. The market has subtracted the entire Q2 step. Whatever it is worried about is worth more than that step, and neither of us has read what it is.

I'd change my mind on: 1. A 10-Q debt note showing the reclass is funded or refinanced. 2. The Q3 guide and print holding revenue near $1.2B and operating margin near 19–20%. 3. Ophir proceeds committed to debt paydown. 4. A close above 249.15 on rising volume.

Until then, a bounce here is a trade inside a downtrend. Before sizing, I'd want your target price and the probabilities behind it. Bear Analyst: # Bear Final Rebuttal: MKSI at $215.51 (2026-10-21)

You ended on one question, so I answer it directly in section 5. First, what I'm conceding.

Where I'm giving ground¶

EV/EBITDA is the better frame. I rebuilt your table and the arithmetic holds.
The share count leans your way. If the roughly 5M-share gap between 72.6M diluted and 67.6M outstanding is a convertible already inside the $4.2B of debt, you've counted it twice. The stock would then sit nearer 13x than 14x on Q2 run-rate EBITDA.
This isn't distress. $14.6B of market cap sits on $4.2B of debt. The debt is a dated question inside the valuation, not a solvency call.
"The market read the filings and rejected them" was too tidy. The repricing came in legs. I take that up in section 3.

1. Your edge is smaller than the error in your inputs¶

Your own conclusion is +2%, about $5 a share. In your table, probability-weighted run-rate EBITDA is about $1.29B, so one EBITDA turn is worth about $18 a share. Your edge is under a third of a turn.

At 15x on that weighted EBITDA you get $215, which is today's price. The +2% comes entirely from using 16x instead of 15x in the two weaker scenarios. Take one turn off every scenario and keep your probabilities:

Scenario (your weight)	Your value	One turn lower
Growth continues (25%)	$268	$247
Q2 holds (35%)	$232	$214
10% give-back (25%)	$193	$178
Full reversal (15%)	$161	$148
Weighted	$221 (+2%)	$203 (−6%)

Two smaller points. The 20/30/30/20 weights aren't mine. I used three equal scenarios, so the −1% comparison is your construction. And the $92M D&A, the 72.6M shares and the 15x are all inferences. The share count may help you, but D&A and the multiple may not. A +2% edge doesn't survive those error bars.

2. Your gate lets in your own −10% case¶

Your give-back scenario is revenue of about $1,123M at a roughly 16.5% operating margin. Your pass conditions are revenue below about $1.12B or margin below about 16%. That guide clears the gate, so you'd buy a scenario your own table values at $193.

Your "guide down about 10%" case is worth −12% on your weights, yet it sits right at the edge of the pass line. The gate should be flat-or-better, not "not worse than −10%."

The guide is also public. You conceded that it's in the August filings. The stock is down about 35% from its 8/4 close with that guide available. So reading it isn't a catalyst, it's homework, and I agree you should do it before sizing. A "clean" guide gets you to +7% ($231) on your weights, which is the 10 EMA, the level I'm already treating as the first confirmation. At 1.5–2% of capital, +2% is 0.04% of the portfolio and +7% is 0.14%.

Our operating data ends on 6/30. There is no Q3 order data, no guide and no customer commentary. The only series that updates after that date is price, and it says −35%.

Your 18x-in-August anchor doesn't help either. On your inputs the same Q2 run-rate was about 26x at $444 on 6/30, about 18x at $302 and about 14x now. If 18x is a floor, then 26x is a target. I read the sequence as a market that has been steadily lowering what it will pay for a run-rate it doesn't trust to last.

The stock also peaked on the last day of the best quarter in the company's history. Cyclicals typically peak before their earnings do (general knowledge, not from the tools). Strong reported numbers fit your view and mine equally well, so they can't settle it.

You called the unexplained 30% slide "the real residual risk," and you size small because of it. Sizing doesn't explain a drop. It only puts a price on not knowing.

4. Debt, briefly¶

If the reclass is a plain maturity, it falls between January and March 2027, two to five months out, and it was still current at 6/30. Lenders look at trailing and through-cycle numbers. TTM EBITDA of $1.06B means 3.5x net leverage, or about 3.3x after Ophir on a Q1 run-rate. The 2.3x figure needs Q2 to persist, which is the same assumption again. A refinancing after 6/30 would be in an 8-K I can't see. That's the one document that could take this issue off the table.

5. Your question: what multiple would I own it at?¶

13x Q2 run-rate EBITDA, about $195, if the guide holds near $1.2B and the debt note is clean.

This number comes from your table. 13x on Q2 run-rate gives an EV of about $17.8B, the same as your 16x on give-back EBITDA ($193). I'm asking to be paid in full in the middle-bad case and to own the other two as upside. On your values and your weights, a $195 entry gives about +13% expected value ($221 / $195) with a worst case of −17% instead of −25%. At 12x ($176) I'd add. So we're about $20 apart on the no-regret entry, not $40.

There are two routes to yes: - Price: about $195 or lower, with the guide and debt note checked first. That would mean breaking the 3/9 low of $200.16. - Evidence: a close above $231 on volume, then 249.15, or a Q3 print that holds revenue near $1.2B and operating margin near 19–20%.

Bottom line¶

The bull case has gone from "cheap on either basis" to +2% expected value, a 1.5–2% starter position and a gate that admits its own −10% scenario. What remains is a bounce candidate inside a confirmed downtrend: all three SuperTrends are down, ADX is 45, the stock is levered about 3.5x net, beta is 2, and a debt date sits two to five months out. The FOMC (10/28–29) and the Q3 print both come before any of that is resolved.

I wouldn't buy MKSI at $215.51. I'd change my mind on any of these: 1. The 10-Q debt note shows the maturity funded or refinanced. 2. The Q3 guide and print hold revenue near $1.2B and margin near 19–20%. 3. Ophir proceeds are committed to debt paydown. 4. The price reaches about $195 with 1–3 checked, or a close above $231 and then 249.15 comes on rising volume. Bear Analyst: # Bear Closing: MKSI at $215.51 (2026-10-21)

Your question was whether I'd buy a starter at $215, wait for $195, or wait for a $231 reclaim. I'd wait, and I'd prefer to wait for evidence over a price. Here is why, after what I'm giving you.

Where I'm giving ground¶

Your multiple asymmetry is right. Downside cases deserve higher multiples because trough earnings look expensive. My blanket one-turn haircut penalized them twice, so I'm adopting your up-cases-only version.
The share count can help you. If the roughly 5M-share gap is a convert already counted in debt, every value in your table is understated by up to 7%. That is a real upside risk to my side, and it is in the 10-Q you're going to read.
Price can't separate our stories. A momentum multiple unwinding and a market doubting peak margins look the same on the tape. The 26x at $444 may also have predated the print.
$195 is against the tape. It sits below the 3/9 low of 200.16, and you're right that a clean-filings stock there would be telling us something. I'm demoting it from a trigger to a ceiling on what I'd pay without confirmation.
Your process is sound. Read first, size for the gap, and no position if you can't get to the documents.

1. Your gate buys +1% to +7%¶

I applied your own up-cases-only haircut to your own scenario values and weights:

Weights	Your multiples	Up-cases −1 turn
Original (25/35/25/15)	$221 (+2%)	$209 (−3%)
Clean guide (30/45/20/5)	$231 (+7%)	$217 (+1%)
Guide down ~10% (0/15/55/30)	$189 (−12%)	$187 (−13%)

You only buy in the middle row, so the entire payoff of clearing the gate is +1% to +7%. That is less than one EBITDA turn, which is worth about $18–19 a share. It is also inside the error bars you've already admitted on D&A (an inference), shares (72.6M vs 67.6M), tax (11% vs 18%) and the multiple. Those errors cut both ways, which is exactly why I can't call it an edge.

2. The gate tests the wrong period¶

The guide and the debt note both predate 10/6. On that day MKSI closed at 281, two months after the Q2 numbers were public, and then fell 25% in two weeks. Whatever drove October happened after both documents were published.

You wrote that a break below 200 with clean filings would mean "the market is pricing something outside the filings." That is already true at $215. Clean filings explain the 6/30 balance sheet and an early-August forecast. They can't explain a leg that came later, such as an order slowdown, customer capex cuts or a peer read-through. The Lam, KLA, AMAT and ASML reports on the macro report's watch list may carry some of that, and the Q3 print will.

You also conceded that cyclical stocks peak before their earnings, and no filing-based gate tests that. A guide issued before the turn will look clean right up until it doesn't.

3. With no edge, waiting is nearly free¶

If the valuation edge is within the error bars, buying early doesn't earn a premium for taking the event risk. It only takes the risk.

What's coming: the FOMC on 10/28–29 (86% hold, 12% hike, 97% no cuts in 2026) and the Q3 print. The date for the print is unconfirmed, though early November is typical.
Gap risk is real. MKSI has had three single-day drops of 9.5% or more since late July: −9.6%, −9.7% and −10.5%.
Waiting for the 10 EMA (about $231) costs $15, or 7%. At your 1.5–2% size, that is 0.11–0.14% of capital. A −30% gap on the same position costs about 0.5%.

Those numbers are tiny either way, and that is my point. A position small enough to be harmless is small enough to be pointless. I agree with your process, but I don't see a reason to own the stock while it runs.

4. What the bear case still rests on¶

Everything verifiable is full or unresolved.

Valuation: 34x GAAP, about 17x TTM EV/EBITDA and about 30x FCF. Any cheaper figure depends on Q2 being the new run-rate.
Leverage: about 3.5x net on TTM EBITDA (about 3.3x after Ophir on a Q1 run-rate). If the $2.29B reclass is a plain maturity, it falls between January and March 2027, in a market pricing no cuts this year.
Trend: all three SuperTrends are down, ADX is 45, price is under every moving average and the 50 SMA is below the 200 SMA. The only counter-signals (daily TD-9, RSI 30.6, the lower Bollinger Band) are daily-timeframe, and the weekly and monthly TD counts are only +3 of 9.
The tape: it is down about 35% from the 8/4 close of $329, with the Q2 numbers presumably public. Neither of us can name the cause.
Insiders: about $43M sold since February and no purchases in the dataset. That is a constant, not a signal, but nothing in the dataset offsets it either.

My position¶

I wouldn't buy MKSI at $215.51.

Buy triggers (any one):
A daily close above about $231 (the 10 EMA) on rising volume, with 249.15 (the daily SuperTrend flip) as the real confirmation.
A Q3 print and guide that hold revenue near $1.2B and operating margin near 19–20%, with Ophir proceeds committed to debt and the maturity funded or refinanced.
Price-only entry: about $195 at most, only with clean filings, and only after the stock stabilizes there. I won't catch a break below 200.16 without evidence.
If you already own it: the 228–235 zone (the 10/15 close of 228.52, the 10/14 close of 234.50 and the 10 EMA) is the natural place to trim. The Bollinger mid at 251.81 is the outer ceiling for a relief rally.
I'm not shorting the low. RSI is 30.6, the daily TD-9 is complete and price is at the lower band with a 5.7% ATR. My claim is "don't pay up here," not "it can't bounce." The short setup is a failed bounce into that 228–250 area, not $215.

What would change my mind¶

The 10-Q debt note shows the maturity funded or refinanced, and the share-count gap is explained.
The Q3 print holds the Q2 run-rate, which answers the peak-before-earnings question.
Ophir proceeds go to debt paydown.
A close above $231 on volume, then 249.15.

If those arrive, I'll pay a higher price for MKSI than I'm willing to pay today. Bear Analyst: # Bear Final Word: MKSI at $215.51 (2026-10-21)

Your closing is mostly fair, and the plan you've landed on is much more careful than where you started. Here is what I'm taking from it, and why the starter position still doesn't pass.

Where you're right¶

My $231 trigger isn't a value entry. On my own clean-guide figure ($217 with the up-cases-only haircut), buying at $231 is −6% and buying at $249 is −13%. A price trigger buys momentum, not edge, and I'm dropping it as an investment trigger.
The trim/buy collision is real as I wrote it. The 228–235 zone can't be both where I sell bounces and where I buy them.
Waiting isn't free. The tape gaps up as well as down. It rose about 28% from 7/29 to 8/4 and fell 10.5% on 9/14.
Sizing makes our errors tiny. At 1–2% of capital, this is a process disagreement.

1. The repaired version of my triggers¶

The 228–235 zone is a decision zone, not a contradiction. If a rally stalls there on fading volume, I sell it or stay out. If it closes above on rising volume, my failed-bounce thesis is wrong and I stop selling. The action depends on the outcome. A buy needs information, which means the Q4 guide, the debt note and where the Ophir cash goes. A close above 249.15 is a trend-follower's trade with a stop back under 231. I wouldn't call it an investment.

2. Your starter is a zero-expected-value position by your own table¶

Pre-guide, your weights give $209 to $221 on the table, which is −3% to +2% versus $215.51.
You said the 10-Q read "eliminates tails, not finds edge." So after clearing it, the starter is still a roughly zero-EV bet on a 5.7% ATR stock.
At 1%, that EV is about −0.03% to +0.02% of capital. A +7% gap makes 0.07%. A −12% gap costs 0.12%. A −30% gap costs 0.3%.
Your add to 2% comes after the guide, at post-gap prices. That is the same as waiting for the print, with a 1% appendix in front.

"I'd rather hold a small position than watch a 10% gap from the sidelines" is a regret argument, not an expected-value one. If outcomes are roughly symmetric at zero EV, the sideline has the same expectation with less variance. The sideline also avoids the one skew you've identified, a debt date in Q1 2027. I'm not saying holding is wrong. I'm saying nothing in the numbers pays for the risk.

3. What a clean guide has to beat¶

The Q3 quarter ended 9/30 and the October drop came after it. The Q4 guide is the real information, and you've moved your decision point there. I agree with that. But a stock down 25% in two weeks, with the cause unnamed, has already repriced for something. For a guide to be a positive surprise, it has to beat whatever that is. For it to disappoint, it only has to be ordinary. I can't size that asymmetry from these tools, and it's one more reason I'd rather see the print than guess at it.

4. The debt is still the dated item¶

Current liabilities went from $927M to $2,291M by 3/31 and were still $2,424M at 6/30.
If it's a plain maturity, it falls between January and March 2027.
Net leverage is about 3.5x on TTM EBITDA and about 3.3x after Ophir on a Q1 run-rate. Your 3.0x and 2.3x figures both need Q2 to persist.
Reading the 10-Q shows the 6/30 position. A refinancing after that date would be in an 8-K, and neither of us has seen one.
This isn't a solvency call. $14.6B of equity sits above $4.2B of debt. It's a dated item that I want resolved before paying a full multiple.

5. What I'd do¶

I wouldn't buy MKSI at $215.51, and I'm not shorting here either. RSI is 30.6, the daily TD-9 is complete and price is at the lower band, so a bounce is plausible. My view is "don't pay up for a bounce inside a confirmed downtrend." All three SuperTrends are down, ADX is 45 and price is under every average.

Buy conditions: 1. The Q4 guide holds revenue near $1.2B or better with operating margin around 18–20%. 2. The debt maturity is funded or refinanced, and the share-count gap is explained. 3. Ophir proceeds go to debt paydown. 4. If price comes first, at most about $195, and only with 1–2 checked and the stock stabilizing. I wouldn't catch a break of 200.16 on faith.

If you own it: trim into 228–235 if the rally stalls on fading volume. The Bollinger mid at 251.81 is the outer ceiling for a relief rally.

Where I could be wrong¶

The share-count gap is a convert already counted in debt. That would put the stock nearer 13x than 14x on Q2 run-rate EBITDA, and every value in your table would be understated by up to about 7%.
Q2 persists and the guide shows it. At 15x on Q2 run-rate EBITDA, the value is about $232, and a stock gapping toward $250 would show I was too cautious.
The October drop was a sector de-rating and not a company warning. I can't rule that out. I can't confirm it either.

We agree that the numbers don't support an edge today and that the documents decide it. That is the case for waiting, and a 1% position doesn't change what we'd learn from them. I'd change my mind on the guide, the debt note and Ophir. Until they arrive, I'd rather pay a higher price with the evidence than a lower one without it.

Research Manager¶

Recommendation: Underweight

Rationale: This debate converged more than most, so the call comes down to what's left once both sides' concessions are counted. The bull opened strong. Q2 FY26 revenue was $1,248M, up 28% YoY and up 15.8% sequentially. Operating margin went from 13.8% to 20.1%, GAAP EPS was $2.41 against $0.92, and Q2 FCF was about $189M, or 1.08x net income. Against that, the stock is down 51.5% from the $444 peak and trades around 14x Q2 run-rate EBITDA (about 13x if the roughly 5M-share gap is a convertible already counted in debt). The bull also has real bounce signals: RSI 30.6, a completed daily TD-9 and price at the lower Bollinger Band near 204.60. The bear took most of the rest. Verified multiples aren't cheap: 34x TTM GAAP, about 17x TTM EV/EBITDA and about 30x FCF. The 12.3x forward P/E rests on an unreconciled $17.58 that the bull withdrew. Current liabilities jumped from $927M to $2,291M at 3/31 and were still $2,424M at 6/30, which points to a maturity around Jan to Mar 2027 at about 3.3 to 3.5x net leverage, with no refinancing visible in our data. The stock is down about 35% since the 8/4 close of $329, after the Q2 numbers were likely public. The October leg from 281 to 211 came after both the guide and the 6/30 balance sheet were out, and neither side could explain it. The trend is fully bearish: all three SuperTrends are down, ADX is 45 and price is under every moving average. What decided it is the bull's own math. On his scenario table with the up-cases-only haircut he accepted, expected value is about -3% to +2%. He conceded that is zero edge inside his input error bars (D&A, share count, an 11% vs 18% tax rate, the multiple). He conceded that his filings gate tests the wrong period. His final ask was a conditional 1% starter, which is well below a standard weight. So even the bull isn't arguing for full exposure. That leaves a zero-EV, beta-2, 5.7%-ATR position facing a skewed set of risks: a dated debt maturity, an unexplained post-filing drop, and FOMC (10/28-29) plus the Q3 print inside two weeks. I'm not going to Sell. The earnings look real and cash-backed, this isn't distress ($14.6B of equity over $4.2B of debt), the stock is oversold, and the bear himself won't short the low. Hold doesn't fit either, because the risk/reward isn't balanced once you include the dated and unexplained risks against no valuation edge. Underweight it is: below-standard exposure, trimmed into strength rather than dumped at an oversold low, with clear conditions to rebuild. Data gaps to note: we haven't seen the 10-Q debt note, convert terms, the non-GAAP reconciliation, the Q3 guide, the Q2 report date, any post-6/30 8-K, MKSI's YTD figure, FRED macro data, or any cause for the October drop.

Strategic Actions: 1) Target 40-50% of a standard allocation into the Q3 print. Do not initiate a new position at $215.51, and do not short here, since RSI 30.6, the TD-9 and the lower band make a bounce plausible. 2) If you're at full standard weight, trim in two pieces. Take about a third of the reduction now to cut gap exposure ahead of FOMC on 10/28-29. Sell the rest into a relief rally to the 228-235 zone (10/15 close 228.52, 10/14 close 234.50, 10 EMA about 231) if it stalls on fading volume. Time stop: if no bounce by about 10/27, finish the trim at market so the reduced size is in place before FOMC and the print. 3) Risk line: a weekly close below 200.16 (the 3/9 low) cuts exposure to 25% of standard or less until the filings are read. Size for the gap, not a stop. ATR is about $12 (5.7%), and the stock has had three single-day drops of 9.5-10.5% since late July. Keep the residual position small enough that a -30% gap is a minor portfolio hit. 4) Homework before any re-add: read the Q2 10-Q and release for the debt note (instrument, maturity, settlement and convert terms), the diluted-share gap (72.6M vs 67.6M), the non-GAAP reconciliation and the Q3 guide. Check for a post-6/30 refinancing 8-K and for the use of the $650M Ophir proceeds. Also read the Lam, KLA, AMAT and ASML reports for WFE demand read-through. 5) Upgrade path back to standard weight, or Overweight if several land together: the Q3 print and Q4 guide hold revenue near $1.2B or better with operating margin at 18-20%, the maturity is funded or refinanced, the share-count gap is explained, and Ophir proceeds go to debt. A close above about $231 on rising volume, then 249.15 (the daily SuperTrend flip), is a confirmation add only when paired with that information, not on its own. A price-only re-add happens no higher than about $195, and only with the filings checked and the stock stabilizing there. Don't catch a break of 200.16 blind. 6) Downgrade to Sell (exit the residual) if any of these hit: a guide implying revenue below about $1.12B or operating margin below about 16%, an unfunded maturity inside Q1 2027, convert terms that force cash settlement on bad terms, Ophir proceeds not directed to debt, or a Q3 print that reads as the margin peak. 7) If you hold the residual into a relief rally, treat the Bollinger mid at about 251.81 as the outer ceiling for further trimming unless the upgrade conditions are met.

III. Trading Team Plan¶

Trader¶

Action: Sell

Reasoning: The research plan is Underweight, which maps to a Sell sized as a trim rather than a full exit. The bull's own scenario math gives roughly zero expected value (about -3% to +2%) inside his input error bars. Against that sit a dated debt maturity (current liabilities of $2.4B, with no refinancing visible), an unexplained post-filing drop from 281 to 211, and FOMC (10/28-29) plus the Q3 print inside two weeks. The technicals are bearish on all three SuperTrend timeframes, ADX is 45 and price is below the 10 EMA, 50 SMA and 200 SMA. RSI 30.6, the daily TD-9 and the lower Bollinger Band make a relief bounce plausible, so trim into strength instead of dumping at an oversold low, and do not short. Portfolio holdings are not provided, so this is expressed relative to the caller's standard weight, and the debt note, convert terms and Q3 guide have not been seen.

Entry Price: 231.0

Stop Loss: 200.16

Position Sizing: Reduce to 40-50% of a standard allocation into the Q3 print. Take about a third of the reduction now, ahead of FOMC. Sell the rest into a bounce to the 228-235 zone, or at market by about 10/27 if no bounce comes. Do not open a new position or short at 215.51. If the weekly close falls below 200.16, cut to 25% of standard or less. Keep the residual small enough that a -30% gap is a minor portfolio hit, since ATR is about 12.24 (5.7%).

FINAL TRANSACTION PROPOSAL: SELL

IV. Risk Management Team Decision¶

Aggressive Analyst¶

Aggressive Analyst: Nobody else has spoken yet, so I'll make the case and answer the objections I expect to hear.

The aggressive move on MKSI right now is not holding on because it's down 52% and looks cheap. It's cutting exposure decisively into a bounce, while keeping enough in the name to profit if the bulls turn out to be right. That's what the Sell/trim does. It takes 40-50% of a standard weight into the print, and it doesn't short at 215.51.

Start with the tape, because it's the loudest evidence. The weekly, monthly and daily SuperTrends are all down. ADX went from 7 to 45 in two weeks, and price is below the 10 EMA, 50 SMA and 200 SMA, with the 50 under the 200. The most telling detail came this week. The Ophir sale to TTM was announced on 10/19, a $650M all-cash deal that should have been a clean positive. The stock closed up about 0.3%, then fell 2% the next day to 211.14, its lowest close since March. When good news can't hold a bid for 24 hours, sellers still control the stock.

Now the conservative analyst will probably say to exit everything, or even short it. I'd push back. RSI is 30.6, the daily TD-9 is complete, price sits just above the lower Bollinger Band, and there's a four-day base at 211-216. The 228-235 zone is only about 1 to 1.6 ATRs away, and the stock has bounced about 9% in a day from similar levels before, after 3/30 and 3/9. Dumping the whole position at an oversold low means giving up the best exit price available in this setup. Shorting it is worse. With a beta of 2.03 and ATR of 5.7%, a squeeze to the 10 EMA at 231 would hurt more than the expected gain from a short. So we sell the bounce and don't chase the drop.

The neutral analyst will likely point to the bull case: revenue up 28%, a 12x forward P/E, and a Zacks note about 60% upside. I'd take those one at a time.

The 12x forward P/E uses $17.58 of forward EPS. Q2 GAAP EPS of $2.41 annualizes to about $9.60, which puts the stock near 22x on GAAP. The Q2 operating margin of 20% against about 14% for the prior six quarters could be a cyclical peak or a one-off, and the report couldn't tell which. The 60% upside figure implies a target around $345, a level the stock traded at in the summer. That's a stale analyst target, not a forecast. The plan's own bull scenario math came out at roughly zero expected value, about -3% to +2%, inside the error bars of its inputs. That's not an edge worth sitting on at full size.

The balance sheet is the part I don't want to be caught flat-footed on. Current liabilities jumped from $927M to $2.29B in Q1 while total liabilities fell, which looks like debt moving into the one-year bucket. Net debt is about $3.7B, roughly 3.5x EBITDA, and the Fed market prices 97% odds of no cuts in 2026. The neutral side will say Ophir's $650M plus $480M of TTM free cash flow can cover this, and that's their best argument. But $650M plus all $454M of cash is about $1.1B, short of the roughly $1.36B that moved. The deal hasn't closed, and we haven't seen the note or its terms. A company that fixed this problem would usually say so, and the stock has dropped 25% in two weeks with no explanation I can find. I don't know what the cause is. I do know that in a drop this sharp, with this much leverage, the market may know more than I do.

Insiders sold about $43M this year and bought nothing, not even at these prices. That may partly reflect blackout windows, so I wouldn't lean on it. The sentiment data is also too thin to override the tape. It covers 11 StockTwits messages, two labeled, and one of those was about TTMI. Retail saying "buying here" into a 25% slide is what dip-buying into a falling knife looks like.

On the calendar, FOMC on 10/28-29 is 86% priced for a hold with a 12% hike tail, and the Q3 print is expected in early November, though I couldn't confirm the date. For a high-beta, levered name, that's a lot of binary risk in a short window. That's why the plan sells about a third of the reduction now, sells the rest into 228-235, and falls back to market by about 10/27 if the bounce doesn't come. If the weekly close breaks 200.16, we cut to 25% or less. The residual should be small enough that a 30% gap is a minor portfolio hit. I don't know the caller's holdings, so all of this is relative to their standard weight.

The risk of being wrong is limited by design. If MKSI rips on a clean Q3 and a refinancing, we still hold half a position and can rebuild above the 10 EMA with confirmation. If the debt note turns out ugly, we've already sold most of the exposure into strength. Waiting for the neutral view to feel safe means trading that asymmetry away. Aggressive Analyst: Let me give some ground first, because you each landed real hits and I'd rather fix the plan than defend its weak spots.

You're both right on sequencing. Selling a third of the reduction up front is too timid. The first tranche is about not knowing what's in the debt note, not about where the chart goes, so I'll take half now. You're also right that a weekly-close stop gets checked on 10/23 and 10/30 and does nothing across FOMC. The neutral analyst's daily close below 200 is better, and I'll adopt it. I'd also take back one thing. I called the Ophir tape the most telling detail, and that was too strong. A 2% drop is about a third of an ATR on this stock. The sale price, a bit over 18x the unit's EBITDA, is close to where the whole company trades at about 17x EV/EBITDA, so the deal is neutral to mildly positive. That breaks the conservative analyst's step from "Ophir can't hold a bid" to "the market is pricing something much bigger." You can't read a $4.7 billion drawdown off a 2% day on a deal that was never going to move the stock much. The October drop is unexplained, and that is the case for trimming. Ophir is not evidence for it. I'll also concede that the 3/9 bounce compares an intraday low to a close, and nobody could trade it. The 3/30 to 3/31 move of 9.2% close to close is real, but it's one case. So the plan can't rest on the bounce, and it doesn't need to.

Now the pushback. The conservative analyst's daily close below 205.62 is the worst piece of risk control on the table. It's 0.8 ATR below here, and the report itself says stops inside one ATR get hit by normal noise. On 10/20 the stock traded 205.62 and closed 2.7% higher. That level also sits next to the 204.60 lower band, where the oversold stack clusters. You'd be selling the residual at the exact spot you accused me of selling, an oversold low, just on a delay. A stop is only worth having if it sits where a break means something. Below 200.16, under the March low and every support in the window, it does.

On the limit order, calling it hope for a bounce is unfair. The neutral analyst put the odds of reaching 228-235 in four sessions at somewhere between a third and a coin flip, but a limit fills on a touch, not a close, so we're at the high end of his range. If it doesn't fill, we sell at market on 10/27, which is your own fallback. Over four sessions the sign of the drift is close to a coin flip. ADX says momentum, but short horizons are where oversold readings have had their best record, a modest effect but a real one. The tranche is about 30 points of standard weight, so the whole bet is worth a couple of points of a standard position either way. That's a cheap option, not a prayer.

On the cash flow, the conservative analyst cherry-picked. The 16% H1 free cash flow drop is entirely Q1. Q2 free cash flow was about $189 million against $136 million a year ago, up 39%, and operating cash flow was $243 million against $165 million. I'd also turn the dilution point around. Net income over diluted EPS implies 71 to 73 million diluted shares against 67.6 million outstanding, which suggests equity-linked securities. The stock tripled in the quarters around that reclassification. A convertible classified current because a conversion trigger was met would fit both facts. I can't prove that, and the 10-Q footnote settles it either way. But the conservative's evidence for the worst case fits the benign case better. The cash reconciliation gap is about $100 million against a $14.6 billion market cap, so I'd park it as a footnote question.

Two more of the conservative analyst's points. He says the plan treats 25% as acceptable when wrong, so 25% should be the size now. Size follows evidence. After a break below the March low the base thesis is dead, and before that it isn't. He's right that "we've already sold most of the exposure" was loose. At a 40% residual we've sold about 60%, and the rest rides into the print.

To the neutral analyst: the beta point is fair. Half weight at beta 2 is roughly market sensitivity. That's why I won't argue for anything above the low end of the plan's range. I also accept that FOMC is a smaller binary than I made it, given hike odds falling 18 points while the stock fell about 8%. That makes the Q3 date and the filing the real events. I'd keep 10/27 as the deadline for the middle tranche anyway. A tranche we've already decided to sell shouldn't drift into a position because we kept hoping.

Your best point is the 10-Q. If the June 30 balance sheet is in our data, the filing is out, and this is a thirty-minute read. If it shows a term maturity inside twelve months with no refinancing path, I'd go to 25-30% immediately. If it's equity-linked or already refinanced, I'd hold about 40%.

I also have to be honest about the sizing gap. The difference between 25% and 40% is 15 points of standard weight. A 30% gap costs 4.5 points of a standard position more at 40%. A move to the daily SuperTrend flip near 249 is worth about 2.3 points, and a retake of 300 is worth about 6. That is small enough that the footnote and the caller's loss number should decide it, not me. The real money is in execution errors: selling the residual at 205, being stopped out inside the noise, and rebuilding late. Each costs more than the sizing gap.

So my plan is a Sell as a trim, with no short. Sell half the reduction now. Put the middle tranche on limits at 228-235 with a market fill on the 10/27 close. Hold about 40% into the print, or 25-30% if the footnote is ugly. Cut to 15-25% on a daily close below 200. Rebuild in two steps, first on a close above the 10 EMA on rising volume, then on a daily SuperTrend flip near 249. I don't know the caller's holdings, so they should check the residual against a loss number they've picked in advance. The point is to act decisively on the unknown without being shaken out of the position by noise. Aggressive Analyst: We're closer than the tone suggests, so let me say what I'm giving up, what's left to argue, and what I'd hand the caller.

Conservative, you're right that the middle tranche isn't an option. If you don't believe in drift, a sale at a target or a deadline gets you about today's price. That makes it a covered call with no premium, and I mislabeled it. Neutral, you're right that my oversold-reversal point was a prior I brought in. No report here supports it, and it's weaker when a move is news-driven. I'll call the bounce a coin flip. You're both right on the rebuild rule too. Selling at 231 and buying back at 232 is incoherent. No rebuilding while sell orders are live. The first add comes on a close above about 235 on rising volume, after the filing is read. For the second add, I'll look up the daily SuperTrend level then instead of hard-coding 249. Paying up to 235 for shares we sold near 231 costs a couple of percent on a small tranche, which is cheap.

So what is the middle tranche for? It isn't a bet on the bounce. It's a placeholder until someone reads the 10-Q. The June 30 balance sheet is in our data, so the filing should be public and the market has had it a long time. Reading it first costs about a day of variance, while selling now and rebuying after a benign read costs a round trip. If the note shows a maturity with no refinancing path, the tranche goes at market that day. If it's fine, the limits and the 10/27 deadline run. That's neutral's rule and I'm adopting it. It also makes the 30-versus-33 argument about the pre-read default close to moot, since that default lasts a few hours.

Neutral, your own numbers also gave something away. Thirty sold now and thirty on limits leaves forty, not a third. So your plan is the plan I already put on the table with a different label. Conservative's 35 and 35 leaves thirty. We're arguing over about ten points of standard weight, and neutral's symmetric framing prices it well. A 30% drop from here is about 150 and costs three more points at 40 than at 30. A 30% rise is about 280, where MKSI closed two weeks ago, and it makes three. The stop at 200 is about 7% below the price, so the stop-out case differs by under a point. I can't honestly call that gap an edge, and I won't dress it up as one.

Where I still push is the post-read number, for a different reason than before. A clean footnote doesn't explain October. The reclassification was on the March balance sheet, and the stock paid 444 with it on the books. The slide began in October, long after the Q2 numbers were out. Even a benign note removes one tail and leaves a 25% unexplained drop where it was. So I cap a clean read at 40, maybe 45, and the daily close below 200 stays regardless of what the note says. I'd also add one task nobody has listed. Scan the 8-Ks and press releases since October 6 for anything the headlines missed. The news scan shows no MKSI-specific negative headline, so a 25% drop with no headline is either sector rotation or something we can't see. If the scan is empty and the note is clean, I hold 40. If the note is ugly, I'm at 25 with both of you.

On the share-count clue, I'm being careful because I raised the convertible reading first. The step from about 67.4M to 71M to 73M is real in the rounded numbers, and neutral is right that it fits an equity-linked instrument better than ordinary compensation. But I can't verify it here, and it doesn't justify a bigger size before anyone reads the note. It's evidence, not proof.

My plan for the caller is to sell about 30 to 35 points of standard weight now and put another 30 to 35 on limits at 228-235. That tranche fills at market on the 10/27 close, or the same day if the note is ugly. Hold 30 to 40 into the print. Go to 25 if the note is ugly, and up to 40 or 45 only if it's clearly benign and the 8-K scan is clean. A daily close below 200 cuts the residual to 15 to 20. Rebuild only above about 235 on volume after the read, then again at the daily SuperTrend flip. No short. I don't know the caller's holdings, so they should check the residual against a loss number set in advance. At the top of my range, a 30% gap costs about 12 points of a standard position. Aggressive Analyst: Most of what's left is housekeeping, so I'll take the corrections first.

Neutral, you're right on the timeline, and I was wrong to say the slide began in October. The stock closed at 444 on June 30, was 315 by July 27 and 257 two days later, had a 10% day in September, and now has this October leg. A debt footnote can't explain four legs down. So I'm tightening my own cap to 40 on a clean read, not 45. Conservative's definition of clean is also better than mine: visible terms or a visible refinancing, not merely nothing bad. I'll take the 8-K scan as one-way too. A waiver, a ratings action or a guide cut shrinks the residual, and an empty scan after two quiet weeks adds nothing. The Friday deadline is the best process fix in this debate. If the note is unread by Friday's close, the middle tranche sells at market.

Two refinements to the footnote test, since it carries so much of the plan.

First, "a maturity with no path" should count committed financing, such as an undrawn revolver, as a path if the caller can see one. The sources and uses are tight, not hopeless. Cash of $454M, Ophir's $650M before tax and fees (if it closes), and a year of free cash flow at the $480M TTM rate come to about $1.58B against the $1.36B bucket. That's before dividends and buybacks. So the likeliest answer is "covered but thin," and the plan should say what that does: the residual holds at the planning default and doesn't go higher.

Second, the bond-quote check is a good idea, but it only reads cleanly as a credit signal for a straight note or term loan. If the reclassified item is a convertible, a quote well below par after the stock has halved can just be lost equity optionality. In that case you compare it to the bond floor. Otherwise we could take the ugly branch on a false alarm. The same caution applies to the share-count step. It says something equity-linked exists. I'm not sure it says where the conversion price sits, because if-converted accounting can add shares without the stock being above strike. That's a footnote question, not a conclusion.

I still push on three things.

First, the calendar item says to make the hold-or-trim call on the residual the evening before the print, but it has no criteria. A discretionary vote the night before a binary event is how plans drift. Every revision in this debate has gone toward smaller, and that drift has a pattern. So I'd name the triggers: guidance, a ratings action, a waiver, or a daily close below 200. Without one of those, the residual rides through the print. That's what it's there for. Q2 GAAP EPS was 2.41 against 1.18 in Q1, and the stock is back near its late-March price. If the market is treating Q2 as a peak and Q3 says otherwise, that's where a re-rating comes from. Neutral is right that the other tail is the same size, and I can't promise which one shows up. But the residual is the only place the upside lives, so we shouldn't hedge it away on a feeling.

Second, the rebuild rule needs sizes. "First add above 235, second at the SuperTrend flip" is a direction, not a plan. I'd say about 10 points on the first add and 10 to 15 on the second, with no add taking the total above the loss budget the caller set. That keeps the trim from becoming a round trip.

Third, I want it stated plainly that none of us can read the 10-Q or pull bond quotes with these tools. The caller has to do both, and the plan shouldn't read as though that work is done.

So I'm on Neutral's list. It's still a Sell as a trim, with no short.

Now: sell about 30 points.
Middle tranche: put about 35 on limits at 228-235, with a market fill at Tuesday's close. It sells at once if the note shows a maturity with no path, and at Friday's close if the note is still unread.
Residual: hold about 35 as the planning default. Go to 25 if the note is ugly. Go up to 40 only if the note is clean by Conservative's definition.
Stop: a daily close below 200 cuts the residual to 15-20.
Rebuild: nothing while sell orders are live. Then add in the two sized steps above.

The caller's loss number should override all of it. Aggressive Analyst: I'll start with what Conservative and Neutral have earned, then name a hole in the plan that none of us has mentioned.

On adds, you're both right. The collision Neutral spotted is real: if the limits fill at 232 on Monday and a close above 235 triggers a buy on Tuesday, we've paid a round trip for ten points of weight. Conservative's example settles it for me too. The stock closed at 234.50 on 10/14 and was at 214.83 two sessions later. If it rips before the print, the 35 we hold participates, and that's its job. The cap near 50 is also fair, since 35 plus 10 plus 15 was 60, above the trader's own range. I'll also give up my "covered but thin" arithmetic as a base case. That $1.58 billion spent all the cash, counted Ophir at its gross price before it has closed, and used a full year of free cash flow. It was an upper bound. And a close-based stop fills at the next open, so the 2.5-point cost is a floor.

Two of Conservative's points don't land. First, we already agree on "covered but thin." I said it holds the residual at the default and doesn't raise it, which is what you're asking for. Second, the link between the debt tail and the guidance tail cuts both ways. A weak guide would hurt the equity and the refinancing together, but a strong guide would help both. That makes the residual a concentrated bet on one question: whether Q2's 20% operating margin and 28% growth were a peak or a base. Q2 EPS was 2.41 against 1.18 in Q1, and the stock is back at its late-March price. This is the only place the upside lives, so I won't go below 35 on a feeling. Neutral has it right: the linkage is a reason to require visibility before 40, not a reason 40 can never be reached.

Neutral, the point about asset-sale proceeds is useful, with one extension. A sweep that sends Ophir cash to prepay term debt sounds like the money is spoken for. But if the swept tranche is the one sitting in the $1.36 billion bucket, that cash cleans up the problem. It depends on which tranche, so the Ophir release should be read alongside the note. I also like setting the bond-quote threshold before anyone looks at the quote.

Now the hole. We keep describing the plan as 35 held, but that's the position after the middle tranche sells. Until then, if the limits don't fill, we hold 70 points of standard weight through Tuesday's close. With ATR at 5.7%, a one-standard-deviation move over four sessions is roughly 8 to 10 percent, which is five to seven points on 70. A close below 200 costs about 5 points, not 2.5. A 30% gap to about 150 costs about 21 points. That's still better than the original plan, which held roughly 80 through the same window. But everyone has been fixated on the print, and the nearer exposure is this tranche. We agreed it's worth roughly zero in expectation, so carrying its variance one day longer than the information requires is pure cost. The June 30 balance sheet is in our data, so the filing has been public for months. I'd aim to have the note read by tomorrow's close and keep Friday as the hard backstop, so an unread note can't turn into a default hold.

Neutral's unspoken issue is the right one to end on. If the caller holds nothing, Sell means stay out, and the bounce isn't a reason to buy. If they're above standard weight, they should work to the targets of about 70 and then about 35, not to sale amounts. If they're below, everything scales down.

So the handback is a Sell as a trim, with no short.

Get to about 70 now. Read the debt note and the Ophir release, ideally by tomorrow's close, with Friday as the backstop. Put the next 35 on limits at 228 to 235, with a market fill at Tuesday's close. It sells at once on an ugly note or a bond quote past the threshold written down in advance, and at Friday's close if nobody has read the note. The residual defaults to 35, drops to 25 on an ugly note, and goes toward 40 only if terms or a refinancing are actually visible. A daily close below 200 cuts it to 15 to 20. Nothing is added before the print. After it, add about 10 on a clean guide and a reclaim of the 10 EMA, then the rest at the daily SuperTrend flip with the level looked up then, capped near 50 in total. Look up the Q3 date today.

None of us can open the 10-Q or pull bond quotes with these tools, so the caller has to do both. Until they have, 35 is a placeholder. The caller should set a loss number first and size the residual to fit the 30% gap case, because that number matters more than the last ten points we've been arguing over.

Conservative Analyst¶

Conservative Analyst: I'll start with where I agree with the aggressive analyst, since it narrows the argument. Don't short this. With a beta of 2 and a 5.7% ATR, a squeeze is expensive, and a short has open-ended loss, which is the opposite of my job. You're also right that the bull case is worth roughly zero, so nobody should hold it at full size. My disagreement is with how much risk the trim keeps on, and when it comes off.

Look at the sequencing. The plan sells about a third of the reduction now. If the target is 40-50% of standard weight, that first sale is only 17 to 20 points, which leaves roughly four-fifths of a normal position on while ADX is 45 and all three SuperTrends are down. The rest depends on a bounce to 228-235, or it gets sold at market around 10/27 if the bounce doesn't come. You argued that selling everything at an oversold low gives up the best available exit, but your own fallback is exactly that sale, just later, on the eve of FOMC, at whatever price the stock has by then. The no-bounce case is the case where that price is lower. So the plan is really "hope for a bounce, and sell anyway if it doesn't come."

The evidence for the bounce is thinner than it sounds. A completed daily TD-9, RSI at 30.6 and price near the lower band are all daily-chart signals, the lowest-weight timeframe in the report, which itself calls this a relief bounce inside a downtrend and not a reversal. The weekly and monthly TD counts are only at 3 of 9, the daily z-score is -1.54, not even at -2, and the MACD histogram is still -5.15. RSI can sit near 30 for a long time when ADX is above 40. Today's 2.1% gain came on 717K shares against a normal 1.0 to 2.6M, in a bar that may not be finished. The 9% bounces you cite are two data points, and as I read the report, the 3/9 one compares an intraday low to a close, which nobody could have traded. The zone you want to sell into is also where the stock was closing last week, right under a falling 10 EMA. I don't see a company-specific positive catalyst before your own 10/27 deadline.

That brings me to Ophir, which I agree is the most telling detail, and I'd take it further than you did. Ophir is about 4.5% of the market cap. The stock lost about 25% in two weeks, which is roughly $4.7 billion of value. The market isn't ignoring a $650M cash inflow. It's pricing something much bigger, and neither of us knows what. If a clean positive can't hold a bid for 24 hours, I don't see why the stock owes us 228-235 on schedule.

You did the debt arithmetic honestly, and I'd push it further. The company won't spend every dollar of its cash on debt, the headline $650M is before any tax or fees, and the deal hasn't closed. The $480M of TTM free cash flow that the neutral side will lean on hides a worse recent picture. H1 free cash flow fell about 16% to $217M, Q1 operating cash flow was just $53M, and capex is up 68%. Cash barely moved, from $418M to $454M, after $285M of financing outflows. The report also flags a cash reconciliation gap and derives a diluted share count of 71 to 73M against 67.6M outstanding, which hints at dilutive securities we haven't seen. With 97% odds of no cuts this year and a 12% hike tail, any refinancing happens at today's rates or worse. I don't know that this goes badly, but it's the one item that could turn a drawdown into a gap, and we haven't seen the note.

Now the sizing. The plan says the residual should be small enough that a 30% gap is minor, but it also says hold 40-50% of standard weight, and we don't know the standard weight, so that isn't a risk limit. This stock fell about 18% over a few sessions in late July, 10.5% in one day in September, and 25% in two weeks in October, and none of the reports explain any of them. A 30% gap from here is about 150, and the stock was at 134 a year ago. The stop is a weekly close below 200.16, which is a Friday rule on a name that can move 12 points in a day, so it does nothing in a gap. The plan's answer to being wrong is to cut to 25%. That tells me 25% is the size the plan considers acceptable when things go badly, and the time to be there is before the gap, when there's still a choice.

You said the risk of being wrong is limited by design because we keep half and can rebuild above the 10 EMA. If we only rebuild after a confirmed close above roughly 231, the cost of being smaller is about 7% of upside from here. The cost of holding half through an ugly debt note is a gap through the stop. And "we've already sold most of the exposure into strength" is false in the ugly-note case, because half the position goes into the Q3 print. A zero-expected-value bet at beta 2 doesn't earn half weight, and holding it is regret management, not risk management. I expect the neutral analyst to say hold and wait for the filing. The filing is the thing we can't see, and waiting for it at four-fifths weight is how you find out in a gap.

So I'd keep the Sell and the no-short rule, and change the sizing and timing.

Target size: about 25% of standard weight before the FOMC decision, not 40-50%.
First sale: roughly half of that reduction now, not a third.
Remainder: a limit order at 228-235, with the close on 10/27 as a hard deadline.
Trigger: a daily close below 205.62, the 10/20 low, takes the residual down further, instead of waiting for a weekly close at 200.
Rebuild: only after a close above the 10 EMA and a visible maturity and refinancing plan in the filing or the Q3 release.

Since I don't know the caller's holdings, they should set the residual so that a 30% gap fits a loss number they've picked in advance. At 25% of standard weight, that gap costs about half what it would at the current plan's size. Conservative Analyst: I'll start with what I got wrong, since it's more than I expected.

The 205.62 trigger was a bad line. It's 0.8 ATR below the price, the stock traded there on 10/20 and closed 2.7% higher, and the technical report warns about exactly that kind of stop. A daily close below 200 is better and I'll take it. You're also both right on cash flow. The H1 free cash flow drop is all Q1, and Q2 at about $189 million against $136 million a year ago is a good quarter. I leaned on a number that had already turned. I'll drop FOMC as a main driver too, with hike odds down 18 points in a week. And I accept that you can't get from a 2% Ophir day to "the market is pricing something much bigger." The October drop is unexplained, and that is a reason to size down, not proof the debt note is bad.

Here is where I still don't move.

First, the middle tranche. The aggressive analyst called it a cheap option, and it isn't one. An option costs a premium and has a floor. This is the opposite shape. You keep the shares, cap the gain at 228-235, and take whatever price the stock has on 10/27 if the cap isn't touched. That's a covered call with no premium collected. Ignoring drift, a position that is sold at a target or at a deadline is sold on average at about today's price. So the expected gain over selling now is roughly zero, with extra variance. The tranche only pays if you believe in positive drift. The evidence for drift is a daily TD-9 and an RSI of 30, from the lowest-weight timeframe, with ADX at 45. You said yourself the whole bet is worth a couple of points either way. If it's worth about nothing in expectation, selling it now takes the variance off for free.

Second, which way the footnote moves the size. You both set the default at 40 to 45 percent and cut if the filing is ugly. I'd flip that. Until someone has read the debt note, sit near 30 and let a benign filing earn the way up to 35 or 40. The read costs thirty minutes, and being ten points light for a day costs almost nothing. Being ten points heavy when the footnote comes back ambiguous costs more, and no price stop helps with an ambiguous footnote. I'd also look again at a few inferences for the benign case. The convertible story doesn't fit the tripling, because on March 31, when that balance sheet was struck, the stock was about 229, close to where it is now. The diluted share count fits ordinary stock compensation just as well. Neutral, the market did pay 444 with the liability on the books, but things nobody cares about on the way up become the whole story on the way down. And the sector explanation sits badly with AEIS up 40% and KLA guiding higher. MKSI is lagging its peers, which you noted yourself.

Third, take the aggressive analyst's own sizing arithmetic. Going from 25 to 40 adds 15 points. A 30% gap costs 4.5 points of a standard position. The upside is 2.3 points if it reaches the daily SuperTrend flip near 249 and about 6 if it retakes 300. So you risk 4.5 to make 2.3 or 6. That's the zero-expected-value bet the trader's own scenario math described. I don't need a precise gap probability for this. At zero expected value I'll take the smaller position. And "execution errors cost more than the sizing gap" argues for fewer contingent steps, not for more.

Fourth, there's a contradiction in the plan you both share. You want to sell the middle tranche into 228-235, and you want to start rebuilding on a close above the 10 EMA, which is about 231 and falling. Those are the same price. If the bounce arrives, the plan sells at 231 and buys back at 232. Either the zone is a sell zone or a 10 EMA reclaim is a buy signal. I'd put the first rebuild step above the top of the sell zone, a close above about 235, and only after the filing has been read and the refinancing question answered. The rest comes at the daily SuperTrend flip.

So here's my revised version. I'm moving from 25 to about 30 percent of standard weight into the print. I'd sell roughly 35 points now, which is half the reduction. The rest goes on limits at 228-235 with a market sale at the 10/27 close. The Q3 date is a lookup, and it governs the residual, not that tranche. A daily close below 200 cuts the residual to about 15 percent. Read the 10-Q before anything else. A term maturity with no refinancing path takes me to 25, and a clearly benign answer lets me go to 35 or 40. As before, I don't know the caller's holdings, so they should check that a 30% gap, to about 150, fits a loss number they picked in advance. Conservative Analyst: I'll start with what I'm conceding, because Neutral caught a real inconsistency. I said the middle tranche is a covered call with no premium and that selling it now takes variance off for free, and then I wrote a plan that puts it on limits anyway. Your fix is right. It's a roughly zero-expected-value timing choice, so let the footnote decide it. You're also right on the convertible reading. I tested it against today's price when the right test is the conversion price, which we don't have. The share count stepping from about 67.4 million to 71 and then 72 or 73 million in the quarter the liabilities moved is real evidence, even with rounding.

That same clue is where I'd tighten the plan, because "benign if equity-linked" is only benign while the equity part works. The stock has roughly halved from its peak. An instrument that was in the money when the balance sheet was struck may not be now, and if holders don't convert, the principal is a cash claim against $454 million of cash. So "equity-linked on a trigger test" shouldn't count as clean by itself. Clean should mean the conversion price is comfortably below the current price, or settlement is in shares, or the maturity is visibly covered or refinanced. That's still a footnote read, but it's a different question from the one we've been asking.

Aggressive, I'd lean on your cap for a clean read harder than you do. You said a clean note doesn't explain October. It also doesn't explain the late-July gaps or the 10% day in September. That's several unexplained legs down, and the footnote removes only the debt tail. It should move the residual a few points, not take it to 45. My ceiling is 40, and only if the terms or the refinancing are actually visible, not merely not bad. A clean 8-K scan tells us little either, since we've had no headline for two weeks while the stock lost a quarter of its value.

On sizing, I can't honestly call the gap between 30 and 40 an edge. Neutral's symmetric framing is right in percentages: 30% down is about 150, 30% up is about 280, and ten extra points is about three points of a standard position either way. My argument isn't from probability. One tail has 3.5x leverage and a $1.36 billion bucket in it. The other needs the stock to retake a falling 10 EMA, then the 50 and 200 SMAs at 261 and 277. When I can't price either tail, the smaller number breaks the tie. Neutral, Aggressive also caught that your 30 now plus 30 on limits leaves 40, not a third, so say which you mean.

The process matters more than the last ten points. "Someone reads the 10-Q" carries most of this plan and nobody has said when. Aggressive, you said the pre-read default lasts a few hours. I hope so, but the plan should say what happens if it doesn't. Give the read a deadline of Friday's close, the same day as the weekly check. If the note hasn't been read and understood by then, sell the limit tranche at market instead of waiting for Tuesday. That way, not reading it can't turn into holding more risk by default.

My plan is to sell about 35 points of standard weight now. Another 35 goes on limits at 228 to 235, with a market fill at Tuesday's close. It fills at once if the note shows a maturity with no path, and at Friday's close if the note is still unread. I'd hold about 30 into the print, 25 if the note is ugly, and up to 40 only if the terms are visibly benign. A daily close below 200 takes the residual to 15. There's no rebuilding while sell orders are live. The first add comes above 235 on rising volume after the read, and the second at the daily SuperTrend flip, checking that level then. Look up the Q3 date now, so the call on the residual gets made the evening before the print, not the morning of. And no short.

I don't know the caller's holdings. At 30% of standard weight, a drop to 150 costs about nine points of a standard position, and at 40% it costs twelve. The caller should pick the loss number first and let it set the residual. Conservative Analyst: We've converged enough that I'll spend most of my words on where the plan still leaks. First, the concessions, because each of you earned one.

Neutral, you're right that "the smaller number wins when I can't price the tails" has no floor. Taken seriously, it tells you to sell everything. The caller's loss number has to set the size, and 35 is a fine planning default. I'll stop arguing 30 versus 35. Aggressive, your if-converted point is also right. That method can add shares whether or not the stock is above the conversion price, and a jump in EPS can make an instrument dilutive by itself. Last round I called the share-count step real evidence. I'd now downgrade it to a reason to read the note, not a clue to what's in it. I accept both of your caveats on the footnote test too. A committed facility counts as a path, and a bond quote only reads as a credit signal against straight debt, or against the bond floor if it's a convert. I'd add that "committed" has to cover the bucket after covenant headroom and has to outlast the debt it refinances. And a pre-committed rule beats a vote the night before, so I'll drop that objection.

Now the places I'd still push.

First, rebuilding before the print. Both of you have the first add coming on a close above about 235 on rising volume after the read, and that can happen before early November. But the reason we trim is the print and the debt question. An add on a pre-print breakout puts 10 points back into the binary we just reduced. 235 is also a weak breakout level. The stock closed at 234.50 on 10/14 and was at 214.83 two sessions later. If it rips before the print, the 35 we hold participates, and that's what holding it is for. So both adds should wait until after the print and the guide.

The sizes also add up to more than the thesis allows. 35 plus 10 plus 15 is 60, above the 40-50 ceiling the trader set. At the daily flip near 249, the weekly stop at 319 and the monthly stop at 413 are still above price, so the primary trend is still down. I'd cap the total at about 50 until the footnote and the guide have both come back clean.

Second, the stop. You both quote the 200 stop as costing about 2.5 points of a standard position. That's the loss at the trigger price, which is the best case. A close-based rule executes at the next open, and this stock has a record of opening far from the prior close. It went 315 to 285 to 257 on consecutive closes in July and lost 10.5% in a day in September. The print gap goes straight past the stop. So the caller should test the loss number against the 30% gap case, and treat the stop figure as a floor, not an estimate.

Third, "covered but thin," Aggressive. That arithmetic spends all $454M of cash. It counts a deal that hasn't closed at its gross price, before tax and fees. And it uses a full year of free cash flow before anything else claims it. That's covered only if nothing goes wrong. The two tails also aren't independent. Whether lenders refinance a $1.36B bucket on acceptable terms depends on the same outlook the Q3 guide will reset. So a clean footnote doesn't turn the print into a separate coin flip. A weak guide would hit the equity and make the refinancing harder at the same time. That's why I'd treat "covered but thin" as the 35 default, not a step toward 40, and keep 40 for terms or a refinancing that are actually visible.

On your trigger list, guidance can't be observed before the print, and waivers and ratings actions are rare. In practice the list is the close below 200, and the rule is to ride the residual. I'm fine with that if the residual was sized for the gap. I just want it said plainly, so nobody thinks the triggers protect us going into the print.

On the drift charge, the moves were from 40-50 down to 35 and from a third to half up front, and the Friday deadline and the one-way 8-K rule are what keep drift out of the process.

Here's the version I'd hand back. It's Neutral's list with 35 as the planning default, plus three amendments:

No adds until after the print, and a total capped near 50 until the footnote and guide are both clean.
The loss number tested against the gap, with the stop figure treated as a floor.
"Path" defined as committed financing that covers the bucket after covenant headroom.

It's still a Sell as a trim, with no short. None of us can read the 10-Q or pull bond quotes with these tools, so the caller has to do both before anyone treats the footnote as settled. I also don't know the caller's holdings, so their loss number should override all of this. Conservative Analyst: Most of what's left is housekeeping, so I'll be brief on concessions and spend the time on the soft spots that remain.

Aggressive, your hole is the right one, and it goes further than you took it. I've been treating 35 as the number and 70 as a waypoint, but 70 is where we actually sit until the note is read, and it's twice the residual. A 30% gap costs 21 points there, not 10. The odds of that over four sessions with no scheduled catalyst are lower than over a print, so I won't call them the same risk. Still, the caller's loss number has to be tested against 70 as well as 35. If 21 points doesn't fit, the first step should go lower today instead of waiting for the read. I'll also grant that the residual is where the upside lives. I've never asked for 15. Neutral, you're right that a footnote showing a committed refinancing or a distant maturity mostly decouples the debt tail from the guide, so 40 is reachable.

Now the pushbacks.

First, the read deadline. "Aim for tomorrow's close, with Friday as the backstop" is how a backstop becomes the default. The filing has been public for months and the read takes thirty minutes. Make tomorrow's close the deadline. If the note is unread by then, the middle tranche sells. If someone can read it tonight, tomorrow's open is available, and we should use it.

Second, the timing of Ophir cash. The deal was announced on 10/19 and the quarter ended 9/30. The Q3 balance sheet will therefore show the same current-liability bucket and no Ophir proceeds. The print can only give us commentary on refinancing and use of proceeds. That's another reason no adds belong before the print, and it means "visible" has to come from disclosed terms or a clear statement on the call. I agree with Aggressive that it matters which tranche a sweep would hit, so read the Ophir release next to the note.

Third, the stop, which we've all been casual about. A rule on a close acts after the session is over. This stock has fallen 10.5% in one day and 25% in two weeks. By the time a close-based rule fires, the day's damage is done. We chose closes because of wick noise when the level was 0.8 ATR away. At 200 we're about 1.25 ATR out and below every support in the window. I'd use a resting stop a hair under 200, say 198, which would have survived the 3/9 low of 200.16. If the caller prefers the close rule, they should know the price is gap-through risk, and the 2.5-point cost is a floor.

Fourth, the "concentrated bet on peak versus base." I agree a strong guide would help the equity and the refinancing together. But the shape isn't symmetric. A strong guide eases the bucket without removing it. A weak guide on a 3.5x levered company with $1.36 billion in the current bucket can change what lenders are willing to do in one step, and the equity would gap on that. The market has also had the 28% growth number for weeks, and the stock still trades near 12x forward earnings. That doesn't prove the market is right. It means we can't tell, which is the condition for sizing from the loss budget and not from the upside story.

Fifth, the bond quote. We're all agreeing to set the threshold in advance, which is good. I'd add that term-loan and bond quotes for an issuer like this can be indicative or stale. The write-down should name the source and require a recent trade level. Otherwise the caller is reading a number with no information in it.

Last, the caller's context. Points of standard weight mean nothing until converted to the book. If standard weight is 4% of the portfolio, ten points on a 30% gap is a rounding error. If it's 10%, it's a real drawdown. That conversion is the caller's loss number, and it should decide whether 35 holds. Taxes on a big gain shouldn't set the risk size either.

So the handback is still a Sell as a trim, with no short. Get to about 70 today, lower if 70 fails the loss test. Read the debt note and the Ophir release by tomorrow's close. If the note is ugly or still unread, the next 35 sells that day. Otherwise it sits on limits at 228 to 235 with a market fill at Tuesday's close. The residual defaults to 35, goes to 25 on an ugly note, and goes up to 40 only if terms or a refinancing are visible. A resting stop under 200 cuts it to 15 to 20. Nothing is added before the print, and after it the total is capped near 50. Look up the Q3 date today.

Finally, none of us can open the 10-Q or pull bond quotes with these tools, so the caller has to do both. Until they have, 35 is a placeholder.

Neutral Analyst¶

Neutral Analyst: I'll start with what you two already agree on, because it's a lot. Don't short it, the bull case is worth about zero at full size, and the debt note is the item that could turn a drawdown into a gap. The real disagreement is how big the residual should be and what cuts it. Each of you has one half of that right and one weak spot.

Aggressive first. Selling a third of the reduction now leaves roughly four-fifths of a normal position on through a stretch where all three SuperTrends are down and ADX is 45. The bounce you're counting on is also less likely than it sounds. The stock has to rise 6 to 9 percent to reach 228-235 in four sessions (Thursday through the 10/27 close). A rough random walk on the ATR gives that somewhere between a one-in-three and a coin-flip chance, before any downward drift. So the 10/27 market sale is probably the main exit for that tranche, and the plan should say so. Your stop has a timing problem too. A weekly close below 200.16 gets checked this Friday and then 10/30, which is after FOMC, so it does nothing in the window you say you're worried about. And at a beta of 2, 40-50% weight still carries about the market sensitivity of a full-sized average stock. That isn't much of a trim.

Conservative, you're right on that sequencing, but several of your supports lean harder than the data allows. You say recent cash flow is worse than the TTM figure hides. The H1 free cash flow drop of 16% is all Q1. Q2 free cash flow was about $189M against $136M a year earlier, up about 39%, and operating cash flow was $243M against $165M. Capex rose 68% in a quarter where revenue grew 16% sequentially, which looks like a working-capital hit and a capacity build, not deterioration. On refinancing, even if the $1.36B costs 200 basis points more, that's about $27M a year against roughly $1.06B of EBITDA. The danger there is access to credit, not price, and access is a tail risk. Ophir would also take net leverage from about 3.5x to about 3.0x before tax and fees. That's modest, but it isn't nothing.

I also don't think the liability jump can explain October. It sat on the March 31 balance sheet, which should have been public since the spring, and the stock traded at 315 in May and 444 in late June with it on the books. The market had it and paid up. I agree Ophir not holding a bid is telling, but "the market is pricing something much bigger" is one reading. The other is a beta-2 stock that tripled in eight months giving most of it back while semis lose relative strength after the MU miss. That sits oddly with AEIS up 40% for the year, but it's the only sector explanation on the table. Rates don't explain it either. Hike odds fell 18 points this week while the stock dropped about 8%, so FOMC is a smaller binary than either of you is treating it.

Your trigger worries me most. A daily close below 205.62 is about 0.8 ATR below here, and the technical report itself says stops inside one ATR get hit by normal noise. The stock traded 205.62 intraday on 10/20 and closed at 211. You'd be dumping the residual at the potential low of a bounce, which is exactly the mistake you accuse the aggressive side of. Your cost of being small is also understated. Seven percent to the 10 EMA is only the first stop. The daily SuperTrend flips about 16% up, and a clean Q3 at 12x forward earnings with 28% revenue growth could re-rate this quickly. Rebuilding only above a falling 10 EMA and after a visible refinancing plan means buying back higher.

Here's where I land. Keep the Sell and the no-short rule, and aim for about a third of standard weight into the print, between your 25% and the plan's 40-50%. Sell roughly half the reduction now, about 30 points of standard weight. That tranche is about the unknown, not the chart. Neither a bounce nor a base tells us what's in the debt note, and the reduction takes the risk off in proportion to the uncertainty. Put the next tranche on limits at 228-235 with a market fill at the 10/27 close, and expect the market fill. Hold the last third through the print with a stop on a daily close below 200. That sits below every support in the window (the 3/9 low at 200.16, the 3/30 low at 208.12, the lower band at 204.60) and about 1.25 ATRs away, so noise shouldn't trip it. If it does trip, cut the residual to 15-20%. At a third of standard weight, that stop costs about 2.5% of a standard position, and a 30% gap costs a bit over 10%. The caller can check that against a loss number they've picked, since I don't know their holdings.

One thing neither of you raised is that we keep saying we haven't seen the debt note, but the June 30 balance sheet is in our data, so the 10-Q with the footnote should be out. That's a thirty-minute read, not a prediction. The fundamentals report lists three possibilities for the reclassification: a nearing maturity, a convertible becoming convertible, or a covenant issue. You've both leaned toward the worst one. If the footnote shows a term maturity inside twelve months with no refinancing path, take the residual toward 25% now and don't wait for 10/27. If it's an equity-linked instrument classified current on a trigger test, or the refinancing is already lined up, 40-45% is fine. The Q3 date works the same way. The company has announced the call, so the date is a lookup, and the time stop should key to it instead of "about 10/27."

For the rebuild, I'd go in two steps. Add back first on a close above the 10 EMA on rising volume, ideally with a clean print, and add the rest if the daily SuperTrend flips near 249. That avoids both holding a falling knife at size and paying up for confirmation on the entire position. I'd put little weight on the insider selling, since the February and March sales at $214-261 came right before the run to 444. Neutral Analyst: We've converged more than the tone suggests, so let me start with the real gaps. Everyone now agrees on no short, a daily close below 200 as the stop, FOMC being a smaller event than it looked, Ophir not being evidence either way, and the debt footnote being the most valuable thing anyone can read before sizing further. The residuals on the table are 30, about 33, and 40 percent of standard weight. That's ten points apart, so most of what's left is about process.

Conservative, your math on the middle tranche is right. Selling at a target or a deadline with no drift gets you today's price on average, so it's a covered call with no premium. But your own plan puts 35 points on limits at 228-235 with a market fill on the 27^th. You argued for selling that tranche now, then wrote a plan that doesn't. I'd call it what it is, a roughly zero-expected-value timing flip, and let the footnote override it. If the filing is bad, sell the tranche at market that day. If it's fine, let the limits and the deadline run.

Your sizing arithmetic compares unlike moves. You set a 30% gap down against a 16% move to the SuperTrend flip and a 39% move to 300. Thirty percent up from 215.51 is about 280, where MKSI closed on October 6, two weeks ago. So 15 extra points of weight risks about 4.5 points on one tail and makes about 4.5 on the other. That's a symmetric bet between two tails we can't price, and only the footnote updates those odds. I'll still give you the pre-read default, which should sit at the low end, around 30 to 33, not 40.

I don't think your reason for dismissing the convertible reading holds, though. What matters is the stock relative to the conversion price, not relative to today's price. By March 31 it was up about 70% from its October low of 133.86. And there's a clue neither of you raised. Net income divided by diluted EPS gives about 67.4 million shares for each of the three 2025 quarters. It jumps to about 71 million in Q1 FY26 and 72 to 73 million in Q2, the same quarter current liabilities jumped. A plain maturity wouldn't touch the share count, while an equity-linked instrument moving into the money could explain both. Ordinary stock compensation was already in a flat 2025 count, and a 6% step in one quarter is something new. These are rounded inputs, so treat the numbers as plus or minus a million, and I can't confirm any of it with these tools. It does make me less sure of a refinancing cliff than your framing, and it makes "things nobody cares about on the way up" less useful, since that line can explain any drop.

Aggressive, that same clue is evidence for the benign reading, not proof, and it doesn't justify 40% before anyone reads the note. An equity-linked instrument brings its own risks: dilution, and possibly cash settlement of principal, against $454M of cash and $1.36B that moved. I'd also separate your oversold-bounce point from the data. No report here says short-horizon oversold readings have their best record. That's a prior, and the short-term reversal effect is usually weaker when the move is news-driven. We don't know whether this one is. With ADX at 45 and a daily TD-9 as the only exhaustion signal, I'd call the bounce odds a coin flip. You also said the whole tranche is worth a couple of points either way. If that's true, it shouldn't be what the plan is built around.

Conservative caught a real problem with the rebuild rule, and I wrote that rule. It's worse than he said. The 10 EMA is falling two to three points a day, and if the stock sits near 215 it drifts to roughly 222 by the 27^th. A close above it would be a buy signal below the sell zone while limits are still live. So no rebuilding while sell orders are working. The first add-back needs a close above about 235 on rising volume, after the footnote is read. The second comes at the daily SuperTrend flip, but that stop ratchets lower if price doesn't recover, so check the level then instead of hard-coding 249.

Here's where I land on MKSI. Sell about 30 points of standard weight now. Put roughly another 30 on limits at 228-235 with a market fill at the 10/27 close, or sell it immediately if the footnote shows a maturity with no refinancing path. Hold about a third into the print, and drop to 25 if the footnote is ugly. Go up toward 40 only if it's clearly benign, meaning equity-linked on a trigger test or already refinanced. A daily close below 200 cuts the residual to 15 to 20 percent. I don't know the caller's holdings, so they should check that a third of standard weight can absorb a 30% gap, about a 10-point hit to a standard position, against a loss number they chose in advance.

The aggressive version bets on drift nobody can see, and the conservative version reaches almost the same place with more moving parts. The footnote will move the right size more than any argument we have left. Neutral Analyst: Let me clean up my own arithmetic first, since you both caught it. I wrote sell 30 now, 30 on limits, hold a third, and that leaves 40. What I mean, in points of a standard position starting from full weight, is this: sell about 30 now, put about 35 on limits at 228-235, and hold about 35 into the print. If the caller starts below standard weight, scale it down. That sits between your 30 and 40, and I'd hold it loosely. Thirty percent down is about 150 and thirty percent up is about 280, so each ten points of extra weight is worth roughly three points of a standard position in either tail. We're no longer arguing about much.

Conservative, the Friday deadline is the best process point of this round. A plan that depends on someone reading a filing needs a date, and "unread" has to default to the safe side. I'll also take your tighter definition of clean. Equity-linked doesn't clear it on its own. The footnote will give the conversion price, and the test is where that sits against 215 and against the 150 stress case.

I don't follow you on the tie-breaker, though. "When I can't price either tail, the smaller number wins" has no floor. Applied consistently, it tells you to sell everything, because you can never price the tails. What stops it is the loss budget, which you've already said should set the size. So I'd call 35 the planning default and let the caller's number override it in either direction.

Aggressive, I'd correct the timeline, because it matters for your cap. The slide didn't begin in October. The stock closed at 444 on June 30, was 315 by July 27, and was 257 two days later. October is the fourth leg down. Price is now about where it was in late March, while quarterly GAAP EPS went from 1.18 in Q1 to 2.41 in Q2. One reading is that the market sees Q2, with a 20% operating margin against 14% before, as a peak. The debt note says nothing about that. Only the Q3 print and guide will. That's why I'd cap a clean read at 40, not 45. A clean footnote removes one tail but leaves the main binary, and nothing we can see compensates us for holding more into it.

The 8-K scan should only work in one direction. A covenant waiver, a ratings action or a guidance change cuts the residual. An empty scan, after two weeks without a headline, shouldn't add a point.

There's one check nobody has listed, and it goes at the worry that the market knows something we don't. If the company has bonds or a term loan that trade, look at where they're quoted. Lenders have to price refinancing risk directly, and they often move before equity holders can explain themselves. Near par with tight spreads, the maturity tail is mostly off the table. Quoted well below par, take the ugly branch that day without waiting for the 10-Q. That's a few minutes of work, and it tells us more than the equity chart can. I can't see those quotes with my tools, so the caller has to look them up.

Here is what I'd hand back to the trader. It's still a Sell as a trim, and still no short.

Now: Sell about 30 points. That's closer to half the reduction than the third in the original plan, because this tranche is for the unknown debt note, not the chart.
Middle tranche: Put about 35 on limits at 228-235. It gets a market fill at the 10/27 close. It sells the same day if the note shows a maturity with no path or the debt is quoted well down, and at Friday's close if nobody has read the note by then.
Residual: Hold about 35 into the print. Go to 25 if the note is ugly, and up to 40 only if it's clean by Conservative's definition.
Stop: A daily close below 200 cuts the residual to 15-20. It replaces the weekly close, which wouldn't be checked until 10/30.
Rebuild: Don't rebuild while sell orders are live. The first add comes on a close above about 235 on rising volume after the read, and the second at the daily SuperTrend flip, with the level looked up then.
Calendar: Look up the Q3 date today and make the hold-or-trim call on the residual the evening before.

For the caller, at 35 points, a 30% gap to about 150 costs about 10 points of a standard position, and the stop at 200 costs about 2.5. If 10 points is more than the loss they chose in advance, shrink the residual until it fits. If it's well inside, the 40 end is fine. That number matters more than anything we've argued over for the last ten points. Neutral Analyst: We're down to a few real disagreements, plus one thing nobody has said out loud.

On adds before the print, Conservative is right and I'm withdrawing my own rule. The trim exists because of the print and the debt question, so a pre-print add puts exposure back into the event we reduced for. There's also a collision I missed. If the limits fill at 232 on Monday and a close above 235 triggers an add on Tuesday, we've sold and bought within a few points on the same move. Aggressive, you said paying up two percent on a small tranche is cheap. That's true, but it also shows the add is worth very little: ten points of weight for a few sessions. If the stock rips on no news, the 35 we hold participates. So no adds until after the print.

Aggressive is right that the plan needs sizes. After the print, I'd add about ten points on a clean footnote, an acceptable guide, and a close above whatever the 10 EMA has fallen to by then. The second add comes at the daily SuperTrend flip, with the level looked up then, and it's whatever takes the total to the cap. That's the fix for Conservative's 35 plus 10 plus 15 equals 60. I accept a cap near 50, which is the top of the trader's original range. In practice it's a ceiling for a good while. The weekly stop is at 319, so going beyond 50 would be a new decision on new data, not something this debate pre-authorizes.

On "covered but thin," Conservative's critique holds. The 1.58 billion in sources spends all the cash, counts a deal that hasn't closed at its gross price, and uses a full year of free cash flow. I'd add something nobody has raised. Credit agreements often require asset-sale proceeds to prepay term debt, so the Ophir cash could already be spoken for. That's a reason to read the Ophir release for closing conditions, timing and use of proceeds, alongside the debt note. Conservative, I disagree with one step, though. You say the debt tail and the guidance tail aren't independent, so a clean note doesn't make the print a separate coin flip. That's true when the refinancing is still open. If the footnote shows a completed or committed refinancing, or a maturity well out, the debt risk is mostly decoupled. A weak guide then hits the equity but doesn't threaten the balance sheet. The linkage is a reason to require visibility before 40, not a reason 40 can never be reached.

Aggressive's caveat on the bond quote is fair, but it creates a new hazard. If a price below par can mean either credit stress or lost conversion value, the caller will read it through whatever mood they're in. So set the threshold before looking. Write down what quote or yield counts as stress for straight debt, and what comparison to the bond floor counts for a convert. The same discipline applies to the rule that the residual rides into the print unless a named trigger fires. Conservative is right that guidance can't be observed beforehand, so the real protection into the print is the residual's size, not the trigger list. Fine, but say that plainly.

The unspoken issue is what these numbers mean for a caller we know nothing about. Everything here is in points of standard weight. If the caller holds nothing, a Sell means stay out. The trader's plan already says no new position and no short. If they're above standard weight, which is plausible after a ride from 134 to 444 and back, they should think in targets, not sale amounts: about 70 of standard weight after the first step and about 35 after the second. If they're below standard, scale everything down proportionally.

Here's what I'd hand back. It's still a Sell as a trim, with no short. Get to about 70 now, which is roughly half the reduction. Put the next 35 on limits at 228 to 235. It gets a market fill at Tuesday's close, and it sells immediately if the note shows a maturity with no committed path or the debt trades past the pre-set stress threshold. It also sells at Friday's close if nobody has read the note by then. Unread defaults to the safe side. The residual of about 35 is the planning default. It drops to 25 if the note is ugly, and goes up to 40 only if terms or a refinancing are actually visible. A daily close below 200 cuts the residual to 15 to 20, and the caller should treat the roughly 2.5-point cost of that stop as a floor. If the stock gaps, the real test is a drop to about 150, which costs about ten points of a standard position at 35. Nothing is added until after the print. Look up the Q3 date today.

None of us can read the 10-Q, the Ophir release or the bond quotes with these tools. The caller has to do that, and until they have, 35 is a placeholder, not a conclusion. If ten points of loss on a 30% gap is more than the number they set in advance, they should shrink the residual until it fits. Neutral Analyst: We're close enough that I'll settle the three open items and add one inference that I think sharpens the footnote test.

First, the read deadline. Conservative is right. Today is Wednesday, so tomorrow versus Friday is only one session, but a target with a backstop is how the backstop becomes the plan, and the read takes thirty minutes. Tomorrow's close is the deadline. If nobody has read and understood the debt note and the Ophir release by then, the middle tranche sells at market. Aggressive, you already said unread has to default to the safe side, so this should cost you nothing.

Second, the stop, where I need to correct myself. I said 200 was about 1.25 ATRs away, so noise shouldn't trip it. That's true for one day and wrong for the window we're managing. ATR is a one-day measure. With four-session volatility around 10 percent and no drift, the odds of touching a level 8 percent down are roughly 40 percent, and the odds of touching the bottom of the 228-235 zone are about half. So the stop will fire fairly often, and that's acceptable because it trims instead of exiting. A false trigger leaves us at 15-20 instead of 35, which is cheap to be wrong about. On that basis Conservative's resting stop near 198 beats a close-based rule. It acts at the price instead of after the damage, and it sits just under the March low. Two mechanics nobody has stated: it should act on the total position, not just the residual, and it should cancel the sell limits at the same time. Otherwise a bounce fills a limit and takes us below the floor we just set. In a gap it fills at the open, so the roughly 3-point cost on 35, or 6 on 70, is a floor.

Third, the middle tranche has been described loosely. It isn't a fixed 35. It's whatever takes us from 70 to the residual the footnote selects. An ugly note means a residual of 25, so 45 sells immediately. A default or covered-but-thin read means 35, so 35 goes on limits with a market fill at Tuesday's close. A clearly benign read means 40, so 30 goes on limits. Written that way, nobody improvises on the day. Conservative's point about 70 also stands. The caller should test 21 points, a 30 percent gap at 70, against their loss number today, and if it fails, the first sale goes lower now instead of waiting for the read.

Now the inference. It comes from accounting rules, not from the tools, so it's a hypothesis. Current liabilities were 927 at December 31 and 2,291 at March 31. If this is a plain maturity, it was more than a year out at year-end and inside a year at the end of March. That puts it between roughly the end of 2026 and the end of March 2027, unless the company used the refinancing exception to keep it long-term. I've been listing "a distant maturity" as a benign outcome, and it mostly can't be one. If it's a maturity at all, it's close. The benign answers are a refinancing or committed facility that already exists, an equity-linked item that's current on a trigger test and settles in shares, or a classification quirk. A near maturity also means management will have to say something concrete on the Q3 call. That supports holding a modest residual for the answer, and keeping it modest.

On the remaining disagreement, Aggressive says the residual is the only place the upside lives. Conservative says a weak guide hurts the equity and the refinancing together while a strong guide only eases them. Both stories are plausible, and neither is evidence. The 12x forward multiple can't settle it either, because it sits on a $17.58 forward EPS nobody has reconciled, and annualized GAAP puts the stock closer to 22x. You're arguing for the same number from opposite stories, which is a decent sign it's about right. Aggressive is right that the stop and the trigger list don't protect us into the print. The residual's size does, and the caller's loss number should set it.

Here's what I'd hand back. It's a Sell as a trim, with no short. Get to about 70 of standard weight now, lower if 21 points of loss on a 30 percent gap fails the caller's test. If the caller holds nothing, Sell means stay out. If they're above standard, they should work to targets, not sale amounts. If they're below, scale everything down. Read the debt note and the Ophir release by tomorrow's close, and set the bond-quote threshold and source before looking. Then follow the footnote branches above for the middle tranche and the residual, with limits at 228-235 and a market fill at Tuesday's close. The resting stop near 198 takes the total to 15-20 and cancels the limits. Nothing is added before the print. After it, add about 10 on a clean footnote, an acceptable guide and a reclaim of the 10 EMA. Add the rest at the daily SuperTrend flip, with the level looked up then, capped near 50. Look up the Q3 date today.

None of us can open the 10-Q or pull bond quotes with these tools, so until the caller does, 35 is a placeholder.

V. Portfolio Manager Decision¶

Portfolio Manager¶

Rating: Underweight

Executive Summary: Underweight MKSI. Trim now to about 70% of a standard weight, then to a residual of about 35% before the early-November Q3 print. Go to 25% if the debt footnote is ugly, and to 40% only if a refinancing or share-settlement term is actually disclosed. Callers with no position should not open one, and nobody should short at 215.51. Read the 10-Q debt note and the Ophir release by the 10/22 close. The middle tranche sits on limit orders at 228-235 with a market sale at the 10/27 close, and sells immediately if the note is ugly or still unread at the deadline. A resting stop near 198 takes total exposure to 15-20% and cancels open limits. No adds before the print, and rebuilds afterward are capped near 50% of standard. The horizon is 1-3 months with a 204.6 target.

Investment Thesis: DECISION. Underweight matches the Research Manager and the trader's 'Sell sized as a trim'. All three risk analysts ended at 'Sell as a trim, no short' with a 30-40% residual, which is a reduction, not an exit. WHY NOT HOLD. On the bull's own scenario table, after the up-case haircut he accepted, expected value is about -3% to +2%. That is inside his input error bars, so there is no paid-for edge, and the unpriced risks lean one way. (a) Debt: current liabilities went from $927M at 12/31 to $2,291M at 3/31 and $2,424M at 6/30, while total liabilities fell. That fits about $1.36B of debt moving into the one-year bucket. Net debt is about $3.7B, roughly 3.5x EBITDA, and the current ratio fell from about 2.7 to 1.14. As Neutral showed, if this is a plain maturity, the timing of the reclassification puts it between roughly late 2026 and the end of Q1 2027, so a distant maturity is mostly ruled out. The $650M Ophir sale was announced 10/19, after the quarter ended, has not closed and is quoted before tax and fees, so it will not appear on the Q3 balance sheet. Conservative showed that cash of $454M plus Ophir plus a full year of $480M FCF (about $1.58B) covers the bucket only if nothing goes wrong. (b) Unexplained drawdown: the stock fell from 444.39 on 6/30 to 215.51 (-51.5%) in four legs: July gaps (315 to 285 to 257), -10.5% on 9/14, and 281 to 211 in October, none with a headline. Price is back at late-March levels while quarterly GAAP EPS doubled from $1.18 to $2.41. That suggests the market may be treating Q2's 20.1% operating margin (against about 14% for six quarters) as a peak. © Tape: the weekly, monthly and daily SuperTrends are all down (stops 319.34, 413.58 and 249.15). ADX rose from 7 to 45 in two weeks. Price is below the 10 EMA (230.94), 50 SMA (261.29) and 200 SMA (277.08), the 50 is below the 200, and OBV confirms the decline. (d) Valuation is not cheap on verified numbers: 34x TTM GAAP earnings, about 17x EV/EBITDA, about 30x FCF, and about 22x annualized Q2 GAAP EPS of $9.64. The 12.3x forward P/E rests on an unreconciled $17.58 that the bull withdrew. WHY NOT SELL. Earnings are real and backed by cash. Q2 operating cash flow was about $243M against $165M a year earlier, Q2 FCF was about $189M against $136M, and TTM FCF is about 1.09x net income. This is not distress, with about $14.6B of market cap against $4.2B of debt. The daily chart is oversold: RSI 30.6, a completed TD-9, price near the 204.60 lower band, and the MACD histogram narrowing from -5.61 to -5.15. With beta at 2.03 and ATR at 12.24 (5.7%), exiting fully or shorting at an oversold low is poor execution. The residual is where the upside sits if Q3 shows Q2 was a base. WEIGHING THE DEBATE. Conservative won on four points: selling half the reduction up front, a dated deadline after which an unread filing defaults to selling, no adds before the print, and a resting stop instead of a weekly-close rule that would not be checked until 10/30. He also won on capping rebuilds near 50%. Aggressive found the hole in the plan. Until the middle tranche sells, the position is about 70%, where a 30% gap costs about 21 points of a standard position, so the loss budget must be tested at 70%, not just 35%. He was also right that the rebuild steps needed sizes. Neutral showed that the 30-versus-40 gap is symmetric: a 30% drop to about 150 and a 30% rise to about 280 are each worth about 3 points per 10 points of weight. So the footnote and the caller's loss budget should settle it, not argument. Neutral also corrected the stop math: a level about 8% down has roughly a 40% chance of being touched over four sessions, which is acceptable because the stop trims rather than exits. Conservative's 205.62 trigger (0.8 ATR away, inside noise) and Aggressive's oversold-bounce prior were rightly withdrawn. EXECUTION. Weights are in points of standard weight. Callers with no position stay out, callers above standard work to these targets rather than sale amounts, and callers below standard scale everything down. (1) Now: get to about 70%, or lower if a 21-point loss on a 30% gap breaks the caller's loss budget. (2) By the 10/22 close: read the debt note for instrument, maturity, settlement, conversion price and covenant headroom. Read the Ophir release for closing conditions and use of proceeds, including any prepayment sweep and which tranche it hits. Before looking at bond or term-loan quotes, write down the source and the stress threshold (compared with the bond floor if it is a convert). Look up the Q3 date. (3) Branches. Ugly means a near maturity without committed financing that covers the bucket after covenant headroom, debt quoted past the threshold, or the note still unread; in that case sell to 25% at market that day. Covered but thin is the default: hold a 35% residual and put 35 points on limits at 228-235 with a market sale at the 10/27 close. Clearly benign means a committed or completed refinancing, share settlement, or a conversion price comfortably below 215; in that case hold a 40% residual. (4) Resting stop near 198, below the 3/9 low of 200.16: it takes the total to 15-20% and cancels open limits. In a gap it fills at the open, so its roughly 3-point cost at 35% is a minimum. (5) The 8-K scan only cuts: a waiver, ratings action or guidance change reduces the position, and an empty scan adds nothing. (6) No adds before the print. Going into it, the residual's size is the protection. WHAT CHANGES IT. Upgrade toward Hold after the print if revenue holds at about $1.2B or more with an 18-20% operating margin, the maturity is funded, the diluted share-count jump (about 67.4M to 71-73M) is explained, and the Ophir proceeds go to debt. In that case, add about 10 points on a clean footnote plus an acceptable guide plus a close above the 10 EMA on rising volume, then the rest at the daily SuperTrend flip (checking the level then), capped near 50%. Downgrade to Sell on any of these: guided revenue below about $1.12B or operating margin below about 16%, an unfunded maturity inside Q1 2027, convert terms that force cash settlement on bad terms, Ophir proceeds not directed to debt, or a Q3 that reads as the margin peak. PRICE TARGET 204.6. There is no reliable valuation objective: the $17.58 forward EPS is unreconciled and was withdrawn, and the roughly $345 Zacks-implied figure is stale. So I use the technical objective. The report's continuation scenario (all SuperTrends down, ADX 45, weekly and monthly TD counts at only 3 of 9, daily z-score -1.54 with room to -2) points first to the lower Bollinger band at 204.60, which is 215.51 x (1 - 5.1%). That fits the bull's -3% to +2% expected value shifted lower for the lopsided debt and print risks, with relief rallies capped near the 10 EMA (about 231) and the Bollinger mid (251.81). DATA GAPS. These lower confidence to medium: the 10-Q debt and convert terms, the non-GAAP reconciliation, the Q3 date and guide, bond quotes, post-6/30 8-Ks, and any cause for the October drop were not supplied. Today's bar, on 717K shares, may also be incomplete.

Current Price: 215.51

Price Target: 204.6

Confidence: Medium

Time Horizon: 1-3 months

Trading Analysis Report: MKSI¶

I. Analyst Team Reports¶

Market Analyst¶

MKSI (MKS Inc., NMS) Technical Report, as of 2026-10-21¶

1. Summary¶

2. Price Structure (12-month data)¶

3. Trend Indicators¶

4. Momentum¶

5. Volatility and Bands¶

6. Exhaustion and Stretch¶

7. Volume¶

8. Reference Levels (all taken from the data above)¶

9. Scenarios Supported by the Tools¶

10. Limits of This Analysis¶

Key Points Table¶

Sentiment Analyst¶

News Analyst¶

MKSI (MKS Inc.) – Weekly News and Macro Report, 14–21 Oct 2026¶

Data coverage¶

1. Company news: MKSI¶

2. Global and market backdrop¶

3. Prediction markets (Polymarket)¶

4. Implications for MKSI¶

5. Caveats¶

Summary table¶

Fundamentals Analyst¶

MKSI (MKS Inc.) Fundamental Report¶

1. Summary¶

2. Valuation and Market Data (from get_fundamentals)¶

3. Income Statement Trends (quarterly, USD millions)¶

4. Balance Sheet (USD millions)¶

5. Cash Flow (USD millions, year-to-date figures)¶

6. Insider Transactions¶

7. Risks and Strengths¶

8. Items to Verify (outside these tools' scope)¶

9. Summary Table¶

II. Research Team Decision¶

Bull Researcher¶

1. Earnings power: the business just inflected¶

2. Valuation: cheap even on the conservative math¶

3. The Ophir sale reduces the balance-sheet risk¶

4. The setup is washed out¶

5. Where I expect the bear to push¶

6. What would prove me wrong¶

My question for the bear¶

What I concede¶

1. The net-income step is mostly arithmetic¶

2. Your give-back scenario is already close to the price¶

3. Pull-ins, capex and cash flow¶

4. Liquidity¶

5. October¶

6. Insiders¶

7. How I'd actually trade it¶

Your closing point¶

Where you're right¶

1. Your payoff table needs three fixes¶

2. The decline came after the numbers were public¶

3. Liquidity is a gating item, not a disproof¶

4. The plan, in order¶

Where we've ended up¶

What I concede¶

1. Your one-turn haircut contradicts your cyclical argument¶

2. The 26x → 18x → 14x path fits both stories¶

3. The corrected gate¶

4. Your portfolio-impact math¶

Where we've ended up¶

Where you're right¶

1. Your price trigger fails your own table¶

2. Waiting is insurance, and the premium is the gap¶

3. My amended plan¶

4. What's left between us¶

Bull verdict¶

Bear Researcher¶

1. The market has already seen Q2 and kept selling¶

2. Q2 has quality questions you skipped¶

3. The valuation isn't "cheap on either basis"¶

4. The liquidity math doesn't comfort me¶

5. Ophir: the market sold the news¶

6. This isn't washed out¶

7. Quick hits¶

2. Valuation and Market Data (from `get_fundamentals`)¶